锐哥来了 personal page - To The Moon

锐哥来了

锐哥来了

No personal profile

442Follow

6Followers

0Topic

0Badge

2021-09-17

?

Reminder: The Mid-Autumn Festival market closure schedule is here! Hong Kong stocks are closed on the 22nd.

2021-07-20

?

Sorry, the original content has been removed

2021-09-17

?

Hong Kong-listed mainland insurance stocks generally weakened, with Ping An Insurance falling more than 3%.

2021-08-27

?

JD Health, a "pioneer" in internet healthcare

2021-07-29

?

Forbes China Interview with Xia Yu, Chairman of Akeso Biologics: Leaning Towards a Tiger's Den

2021-07-20

?

[Unusual Movement] Wei Xiaoli recovers from today's losses and rebounds.

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3583528354923579","uuid":"3583528354923579","gmtCreate":1620537414910,"gmtModify":1630548055139,"name":"锐哥来了","pinyin":"rgllruigelaile","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":442,"tweetSize":244,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.02%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":884937555,"gmtCreate":1631845236277,"gmtModify":1676530650956,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583528354923579","idStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/884937555","repostId":"1100031374","repostType":4,"repost":{"id":"1100031374","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631587259,"share":"https://ttm.financial/m/news/1100031374?lang=en_US&edition=fundamental","pubTime":"2021-09-14 10:40","market":"us","language":"zh","title":"Reminder: The Mid-Autumn Festival market closure schedule is here! Hong Kong stocks are closed on the 22nd.","url":"https://stock-news.laohu8.com/highlight/detail?id=1100031374","media":"老虎资讯综合","summary":"2021年中秋节假期即将来临！各主要市场休市安排如下：港股：\n\n\n9月22日（周三）休市。9月23日（周四）起照常开市。\n\n\nA股：\n\n\n9月20日（周一）至9月21日（周二）休市。9月22日（周三）起照常开市。\n\n\n美股、英股、澳股、新加坡股市照常交易。\n\n\n沪股通和深股通：\n\n\n9月17日（周五）至9月22日（周三）关闭。9月23日（周四）起照常开通。\n\n\n港股通：\n\n\n9月16日（周四）至9月22日（周三）关闭。9月23日（周四）起照常开通。","content":"<p>The 2021 Mid-Autumn Festival holiday is approaching! Market closure arrangements for each major market are as follows:<img src=\"https://static.tigerbbs.com/a514042f0cc485274181ed3db4bcf541\" tg-width=\"1103\" tg-height=\"746\" width=\"100%\" height=\"auto\"><b>Hong Kong stocks:</b></p><p>The market will be closed on Wednesday, September 22. The market will reopen as usual on Thursday, September 23.</p><p><b>A-shares:</b></p><p>The market will be closed from September 20 (Monday) to September 21 (Tuesday). The market will reopen as usual on Wednesday, September 22.</p><p><b>Trading in the US, UK, Australian, and Singapore stock markets will continue as usual.</b></p><p><b>Shanghai-Hong Kong Stock Connect and Shenzhen-Hong</b></p><p>Closed from Friday, September 17 to Wednesday, September 22. It will reopen as usual from Thursday, September 23.</p><p><b>Hong Kong Stock Connect:</b></p><p>Closed from September 16 (Thursday) to September 22 (Wednesday). It will reopen as usual from Thursday, September 23.</p><p><img src=\"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9\" tg-width=\"2048\" tg-height=\"1311\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reminder: The Mid-Autumn Festival market closure schedule is here! Hong Kong stocks are closed on the 22nd.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReminder: The Mid-Autumn Festival market closure schedule is here! Hong Kong stocks are closed on the 22nd.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-09-14 10:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>The 2021 Mid-Autumn Festival holiday is approaching! Market closure arrangements for each major market are as follows:<img src=\"https://static.tigerbbs.com/a514042f0cc485274181ed3db4bcf541\" tg-width=\"1103\" tg-height=\"746\" width=\"100%\" height=\"auto\"><b>Hong Kong stocks:</b></p><p>The market will be closed on Wednesday, September 22. The market will reopen as usual on Thursday, September 23.</p><p><b>A-shares:</b></p><p>The market will be closed from September 20 (Monday) to September 21 (Tuesday). The market will reopen as usual on Wednesday, September 22.</p><p><b>Trading in the US, UK, Australian, and Singapore stock markets will continue as usual.</b></p><p><b>Shanghai-Hong Kong Stock Connect and Shenzhen-Hong</b></p><p>Closed from Friday, September 17 to Wednesday, September 22. It will reopen as usual from Thursday, September 23.</p><p><b>Hong Kong Stock Connect:</b></p><p>Closed from September 16 (Thursday) to September 22 (Wednesday). It will reopen as usual from Thursday, September 23.</p><p><img src=\"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9\" tg-width=\"2048\" tg-height=\"1311\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100031374","content_text":"2021年中秋节假期即将来临！各主要市场休市安排如下：港股：\n9月22日（周三）休市。9月23日（周四）起照常开市。\nA股：\n9月20日（周一）至9月21日（周二）休市。9月22日（周三）起照常开市。\n美股、英股、澳股、新加坡股市照常交易。\n沪股通和深股通：\n9月17日（周五）至9月22日（周三）关闭。9月23日（周四）起照常开通。\n港股通：\n9月16日（周四）至9月22日（周三）关闭。9月23日（周四）起照常开通。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":6380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884998842,"gmtCreate":1631844289386,"gmtModify":1676530650623,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583528354923579","idStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884998842","repostId":"1115701930","repostType":4,"isVote":1,"tweetType":1,"viewCount":5671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819933613,"gmtCreate":1630026305032,"gmtModify":1676530202919,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583528354923579","idStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819933613","repostId":"1123728452","repostType":2,"repost":{"id":"1123728452","kind":"news","weMediaInfo":{"introduction":"新三板第一媒体，由资深金融人和资深媒体人创办。","home_visible":1,"media_name":"读懂财经","id":"1060193092","head_image":"https://static.tigerbbs.com/0151ecd107de45069beb5d8f191d7326"},"pubTimestamp":1629982601,"share":"https://ttm.financial/m/news/1123728452?lang=en_US&edition=fundamental","pubTime":"2021-08-26 20:56","market":"hk","language":"zh","title":"JD Health, a \"pioneer\" in internet healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=1123728452","media":"读懂财经","summary":"「我们看见的不仅是一个海角，而是一个新的世界」。\n五百年前，历史学家巴若斯记录了他在抵达好望角时的感受：\n1488 年，巴若思乘坐葡萄牙航海家迪亚士率领的船队，从非洲西海岸南亚出发抵达这片海域时，他和","content":"<p>\"What we see is not just a cape, but a new world.\"</p><p>Five hundred years ago, the historian Barros recorded his feelings upon arriving at the Cape of Good Hope:</p><p>When Barros arrived in this area in 1488 aboard a fleet led by the Portuguese navigator Díaz from South Asia off the west coast of Africa, he, like everyone else, was speechless with excitement as he gazed at this long, narrow promontory.</p><p>For a considerable period prior to this, the Cape of Good Hope was known as the Cape of Storms, where huge waves caused by the collision of ocean currents continued year-round. Five hundred years later, when we created the Internet, it was like a navigator discovering a new route around the Cape of Good Hope, opening up opportunities for various industries.<a href=\"https://laohu8.com/S/600628\">New World</a>The door to internet healthcare is no exception.</p><p>The battlefield of Internet healthcare has always been in an environment of multi-party competition. In the past, the social value attribute centered on medical quality has always been the first principle of the medical and health industry. And now,<a href=\"https://laohu8.com/S/06618\">JD Health</a>By positioning itself in the supply chain, it undertook the implementation of more diverse medical service scenarios and eventually occupied a place in the industry.</p><p>From the perspective of financial data<a href=\"https://laohu8.com/S/JD\">JD.com</a>Health continues to experience high growth in the past. In the first half of this year, JD Health's total revenue was RMB 13.64 billion, a year-on-year increase of 55.4%. While business data grew rapidly, JD Health's gross profit margin declined by more than 1% year-on-year for the second consecutive year in the first half of the year. The reason is simple: in the first half of the year, the company provided users with a large number of free online consultations and continued to sell high-quality products at affordable prices to benefit users. Its business strategy can be described as quite \"down-to-earth\".</p><p>In the long run, the continuously improving quality of medical services and the \"down-to-earth\" business strategy are making JD Health's position in Internet healthcare more and more solid.</p><p><b>/01 /</b></p><p><b>The evolving \"ballast\" of the medical ecosystem</b></p><p>JD Health's \"retreat to advance\" strategy is rapidly expanding its medical ecosystem. According to the financial report, the expansion of JD Health's medical ecosystem is mainly reflected in three aspects: the continuous deepening of high-quality medical resources, the further consolidation of supply chain advantages, and the rapid growth of end users.</p><p>On the medical resource side, in order to better provide users with online medical and health services, JD Health has increased its expansion into high-quality medical care. As of June 30, 2021, JD Health Internet Hospital had 24 specialized centers, employing more than 130,000 doctors and medical experts, both in-house and in-house. Among them are well-known doctors such as Academician Han Demin, Professor Hu Dayi, Professor Gao Sihua, and Professor Lin Jiangtao.</p><p>With the addition of more and more national discipline leaders and top doctors, JD Health has further improved its internet medical and health service system. Thanks to this, JD Health received an average of over 160,000 daily online inquiries in the first half of the year, an increase of about 60% compared to the average daily online consultation volume for the whole of 2020.</p><p>As a long-standing strength of JD Health, its supply chain advantages were further strengthened in the first half of the year. On the one hand, JD Health's retail pharmacy business continues to expand its SKUs. As of June 30, 2021, JD Health's retail pharmacy business had more than 40 million products (SKUs), nearly doubling from the end of last year.</p><p>On the other hand, JD Health is also continuously strengthening its fulfillment capabilities. As of the first half of this year, \"JD Medicine Express\" has covered more than 300 cities across the country, providing users with medicine delivery services covering all time periods. Meanwhile, JD Health also helps offline micro and small enterprises reduce costs and increase efficiency through its digital and intelligent supply chain capabilities. Today, JD Health-Alliance Pharmacy has more than 500 cooperative stores, covering 17 provincial-level administrative regions across the country.</p><p>To some extent, JD Health's continuously abundant medical resources and constantly strengthening supply chain advantages are becoming the \"ballast\" of JD Health's entire medical ecosystem.</p><p>The continuous evolution of the \"ballast stone\" has also brought high user growth to JD Health. As of June 30, 2021, JD Health's annual active users reached 109 million in the past 12 months, a net increase of more than 18.8 million compared to the end of 2020.</p><p>At the same time, JD Health's family health management service product, JD Home Doctor, launched in 2020, also performed well. In the first half of 2021, JD Health's user activity rate reached 87%, and the average month-on-month growth rate of users since its launch has been 220%.</p><p><img src=\"https://static.tigerbbs.com/316175643f651a7c496a96da8e03e609\" tg-width=\"600\" tg-height=\"797\" referrerpolicy=\"no-referrer\"></p><p>With the full blossoming of the medical ecosystem, a solid foundation has been laid for the subsequent growth of JD Health.</p><p><b>/02 /</b></p><p><b>From \"medical +\" to \"medical ×\",</b></p><p><b>Full spillover of digital capabilities</b></p><p>While its B2C business continues To grow, JD Health's B2B services have also experienced a full-scale explosion. One obvious phenomenon is that JD Health is increasing its cooperation with all aspects of the healthcare industry chain and fully opening up its digital capabilities.</p><p><img src=\"https://static.tigerbbs.com/509b5bd8c78e99dff3f0872e54d64f1c\" tg-width=\"500\" tg-height=\"333\" referrerpolicy=\"no-referrer\"></p><p>From the current perspective, the implementation of JD Health's B2B services can be concentrated in three aspects: medical and health scenarios, doctor services, and regional medical informatization.</p><p>In terms of medical and health scenarios, JD Health is continuously exploring more diverse service scenarios. For example, the company uses the \"JD Home Doctor\" service as a standard module, along with...<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>Manufacturers of smart medical wearable devices such as speakers and smart bracelets have collaborated to combine \"JD Home Doctor\" products with smart hardware.</p><p>In addition, JD Health has also made breakthroughs in the health insurance scenario. In May, JD Health partnered with Fosun<a href=\"https://laohu8.com/S/UNH\">united health</a>JD.com<a href=\"https://laohu8.com/S/0M6S.UK\">Allianz Insurance</a>Several insurance companies, among others, have jointly launched a managed health insurance service called \"Home Medical Insurance\". With disease prevention and health improvement as its core objectives, this product combines health insurance with JD Health's medical services and health management capabilities, providing families with a one-stop lifelong medical and health services and health protection solution.</p><p>Diversified scenario penetration is of great significance to JD Health. In the short term, more scenarios can enrich JD Health's service and product categories. In the long run, the value of ecosystem companies often depends on the productivity of their ecosystem and their contribution ratio, and scenario extension is an important way to increase the proportion of ecosystem contribution.</p><p>On the doctor service side, JD Health builds a full-scenario operating ecosystem by providing doctors with services such as traffic construction, intelligent online tools, and exclusive rights, and continuously expands its ability to serve doctors.</p><p>For example, providing a safe practice environment for doctors. For both internet hospitals and doctors, clarity of responsibilities and personal risk prevention and control are the fundamental reasons why a doctor is willing to go online to an internet hospital. JD Health protects doctors' personal information security through a data security system, and then avoids online medical risks through process risk control and the purchase of medical liability insurance in online diagnosis and treatment. So, how should we understand the significance behind JD Health's empowerment of doctors?</p><p>In the field of healthcare in Internet plus, the improvement in productivity levels has largely relied on the internet doctor community. In other words, how to continuously enhance the value of Internet plus medical and health to doctors and better assist doctors in carrying out clinical research and diagnosis and treatment activities has naturally become the key to breaking through the current industry.</p><p>This is also the value of JD Health empowering doctors. Improving doctors' abilities through digital means can not only better attract excellent doctors into JD Health's ecosystem, but also bring a virtuous cycle to the entire ecosystem. This is also an ideal development \"path\" in the medical and health field in Internet plus.</p><p>In terms of industry empowerment, JD Health is promoting the sharing of medical and health information through its \"Healthy City\" strategy. Based on this, JD Health has also increased its cooperation with local governments and hospitals to create<a href=\"https://laohu8.com/S/300959\">Online and offline</a>An integrated healthcare service ecosystem. For example, in the first half of this year, JD Health partnered with the First Affiliated Hospital of Henan University of Traditional Chinese Medicine to build Henan's first TCM internet hospital, creating an \"innovative model\" for offline hospitals to improve their operational capabilities by building their own internet hospitals. Looking back over the past few years, JD Health has also reached strategic cooperation agreements with Yinchuan and Beihai to explore the regional implementation of the \"Internet plus Healthcare\" model.</p><p>At this point, JD Health's layout in the B-end market is gradually becoming clear. By penetrating more diverse scenarios, we can deeply explore the diverse needs of users; Technology empowers doctors, connecting high-quality medical resources while improving industry efficiency; Through cooperation with cities across the country, we will promote the overall implementation of medical informatization.</p><p>Looking at a longer timeframe, the multiplier effect brought about by ecosystem openness will gradually be reflected in JD Health.</p><p><b>/03 /</b></p><p><b>JD.com's \"genes\" behind the industry</b></p><p>JD Health is making unprecedented inroads into the medical industry to serve the real economy. This is inseparable from JD.com's long-standing \"physical\" DNA.</p><p>Similar to JD.com's digital transformation of the e-commerce industry, JD Health is transforming the medical and health industry in the same way. This is reflected in two aspects:</p><p>From a starting point perspective, whether it's JD.com or JD Health, digital technology is the starting point for empowering the industry. Looking at the entire internet industry, JD.com has consistently been one of the technology companies with the largest technological investment in China. Over the past four years, JD.com has invested nearly 60 billion yuan in R&D.</p><p>JD.com's technological DNA is also deeply imprinted on JD Health. For a considerable period of time, JD Health has been continuously investing in technological research and development to improve doctor efficiency and optimize user experience.</p><p>In the first half of 2021, JD Health continued to increase its R&D investment, focusing on improving user experience and creating digital and intelligent tools for doctors. Taking JD Home Doctor as an example, through cooperation with smart hardware, JD Home Doctor has \"implanted\" online consultations that originally needed to be completed through a mobile APP into a smart speaker that can summon services by voice, and launched the \"JD Home Doctor Filial Piety Edition\" which is more suitable for the elderly, breaking through the traditional interaction method of online consultation.</p><p>From the underlying logic, both sides are continuously creating social value in different ways. JD.com needs no further explanation. Through solid supply chain management, JD.com's image of \"speed, efficiency, and cost-effectiveness\" in the retail sector has become deeply ingrained in people's minds.</p><p>For JD Health, inclusive healthcare is its focus in creating social value. For example, in response to sudden disasters, JD Health has comprehensively upgraded its emergency response mechanism this year to ensure timely support for residents' health protection.</p><p>This mechanism also played an important role in the recent severe rainstorm disaster in Henan. During the severe rainstorm in Henan, JD Health immediately launched flood prevention and assistance operations, including launching a 24-hour free online consultation zone. At the same time, the company urgently established and dispatched an offline medical rescue team to conduct on-site diagnosis and treatment.</p><p>From a broader perspective, JD Health continuously empowers the medical industry and improves the overall efficiency of the industry through digital means, which is also fulfilling its social responsibility.</p><p>Of course, compared with the retail industry, the process of digitalization transforming the healthcare industry may be longer. However, this also means that once the transformation is completed, JD Health's commercial moat will be even more solid. Considering that healthcare itself is a huge market, as JD Health's healthcare ecosystem takes shape, it is not impossible to \"create another JD.com\".</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health, a \"pioneer\" in internet healthcare</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health, a \"pioneer\" in internet healthcare\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060193092\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/0151ecd107de45069beb5d8f191d7326);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">读懂财经 </p>\n<p class=\"h-time smaller\">2021-08-26 20:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>\"What we see is not just a cape, but a new world.\"</p><p>Five hundred years ago, the historian Barros recorded his feelings upon arriving at the Cape of Good Hope:</p><p>When Barros arrived in this area in 1488 aboard a fleet led by the Portuguese navigator Díaz from South Asia off the west coast of Africa, he, like everyone else, was speechless with excitement as he gazed at this long, narrow promontory.</p><p>For a considerable period prior to this, the Cape of Good Hope was known as the Cape of Storms, where huge waves caused by the collision of ocean currents continued year-round. Five hundred years later, when we created the Internet, it was like a navigator discovering a new route around the Cape of Good Hope, opening up opportunities for various industries.<a href=\"https://laohu8.com/S/600628\">New World</a>The door to internet healthcare is no exception.</p><p>The battlefield of Internet healthcare has always been in an environment of multi-party competition. In the past, the social value attribute centered on medical quality has always been the first principle of the medical and health industry. And now,<a href=\"https://laohu8.com/S/06618\">JD Health</a>By positioning itself in the supply chain, it undertook the implementation of more diverse medical service scenarios and eventually occupied a place in the industry.</p><p>From the perspective of financial data<a href=\"https://laohu8.com/S/JD\">JD.com</a>Health continues to experience high growth in the past. In the first half of this year, JD Health's total revenue was RMB 13.64 billion, a year-on-year increase of 55.4%. While business data grew rapidly, JD Health's gross profit margin declined by more than 1% year-on-year for the second consecutive year in the first half of the year. The reason is simple: in the first half of the year, the company provided users with a large number of free online consultations and continued to sell high-quality products at affordable prices to benefit users. Its business strategy can be described as quite \"down-to-earth\".</p><p>In the long run, the continuously improving quality of medical services and the \"down-to-earth\" business strategy are making JD Health's position in Internet healthcare more and more solid.</p><p><b>/01 /</b></p><p><b>The evolving \"ballast\" of the medical ecosystem</b></p><p>JD Health's \"retreat to advance\" strategy is rapidly expanding its medical ecosystem. According to the financial report, the expansion of JD Health's medical ecosystem is mainly reflected in three aspects: the continuous deepening of high-quality medical resources, the further consolidation of supply chain advantages, and the rapid growth of end users.</p><p>On the medical resource side, in order to better provide users with online medical and health services, JD Health has increased its expansion into high-quality medical care. As of June 30, 2021, JD Health Internet Hospital had 24 specialized centers, employing more than 130,000 doctors and medical experts, both in-house and in-house. Among them are well-known doctors such as Academician Han Demin, Professor Hu Dayi, Professor Gao Sihua, and Professor Lin Jiangtao.</p><p>With the addition of more and more national discipline leaders and top doctors, JD Health has further improved its internet medical and health service system. Thanks to this, JD Health received an average of over 160,000 daily online inquiries in the first half of the year, an increase of about 60% compared to the average daily online consultation volume for the whole of 2020.</p><p>As a long-standing strength of JD Health, its supply chain advantages were further strengthened in the first half of the year. On the one hand, JD Health's retail pharmacy business continues to expand its SKUs. As of June 30, 2021, JD Health's retail pharmacy business had more than 40 million products (SKUs), nearly doubling from the end of last year.</p><p>On the other hand, JD Health is also continuously strengthening its fulfillment capabilities. As of the first half of this year, \"JD Medicine Express\" has covered more than 300 cities across the country, providing users with medicine delivery services covering all time periods. Meanwhile, JD Health also helps offline micro and small enterprises reduce costs and increase efficiency through its digital and intelligent supply chain capabilities. Today, JD Health-Alliance Pharmacy has more than 500 cooperative stores, covering 17 provincial-level administrative regions across the country.</p><p>To some extent, JD Health's continuously abundant medical resources and constantly strengthening supply chain advantages are becoming the \"ballast\" of JD Health's entire medical ecosystem.</p><p>The continuous evolution of the \"ballast stone\" has also brought high user growth to JD Health. As of June 30, 2021, JD Health's annual active users reached 109 million in the past 12 months, a net increase of more than 18.8 million compared to the end of 2020.</p><p>At the same time, JD Health's family health management service product, JD Home Doctor, launched in 2020, also performed well. In the first half of 2021, JD Health's user activity rate reached 87%, and the average month-on-month growth rate of users since its launch has been 220%.</p><p><img src=\"https://static.tigerbbs.com/316175643f651a7c496a96da8e03e609\" tg-width=\"600\" tg-height=\"797\" referrerpolicy=\"no-referrer\"></p><p>With the full blossoming of the medical ecosystem, a solid foundation has been laid for the subsequent growth of JD Health.</p><p><b>/02 /</b></p><p><b>From \"medical +\" to \"medical ×\",</b></p><p><b>Full spillover of digital capabilities</b></p><p>While its B2C business continues To grow, JD Health's B2B services have also experienced a full-scale explosion. One obvious phenomenon is that JD Health is increasing its cooperation with all aspects of the healthcare industry chain and fully opening up its digital capabilities.</p><p><img src=\"https://static.tigerbbs.com/509b5bd8c78e99dff3f0872e54d64f1c\" tg-width=\"500\" tg-height=\"333\" referrerpolicy=\"no-referrer\"></p><p>From the current perspective, the implementation of JD Health's B2B services can be concentrated in three aspects: medical and health scenarios, doctor services, and regional medical informatization.</p><p>In terms of medical and health scenarios, JD Health is continuously exploring more diverse service scenarios. For example, the company uses the \"JD Home Doctor\" service as a standard module, along with...<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>Manufacturers of smart medical wearable devices such as speakers and smart bracelets have collaborated to combine \"JD Home Doctor\" products with smart hardware.</p><p>In addition, JD Health has also made breakthroughs in the health insurance scenario. In May, JD Health partnered with Fosun<a href=\"https://laohu8.com/S/UNH\">united health</a>JD.com<a href=\"https://laohu8.com/S/0M6S.UK\">Allianz Insurance</a>Several insurance companies, among others, have jointly launched a managed health insurance service called \"Home Medical Insurance\". With disease prevention and health improvement as its core objectives, this product combines health insurance with JD Health's medical services and health management capabilities, providing families with a one-stop lifelong medical and health services and health protection solution.</p><p>Diversified scenario penetration is of great significance to JD Health. In the short term, more scenarios can enrich JD Health's service and product categories. In the long run, the value of ecosystem companies often depends on the productivity of their ecosystem and their contribution ratio, and scenario extension is an important way to increase the proportion of ecosystem contribution.</p><p>On the doctor service side, JD Health builds a full-scenario operating ecosystem by providing doctors with services such as traffic construction, intelligent online tools, and exclusive rights, and continuously expands its ability to serve doctors.</p><p>For example, providing a safe practice environment for doctors. For both internet hospitals and doctors, clarity of responsibilities and personal risk prevention and control are the fundamental reasons why a doctor is willing to go online to an internet hospital. JD Health protects doctors' personal information security through a data security system, and then avoids online medical risks through process risk control and the purchase of medical liability insurance in online diagnosis and treatment. So, how should we understand the significance behind JD Health's empowerment of doctors?</p><p>In the field of healthcare in Internet plus, the improvement in productivity levels has largely relied on the internet doctor community. In other words, how to continuously enhance the value of Internet plus medical and health to doctors and better assist doctors in carrying out clinical research and diagnosis and treatment activities has naturally become the key to breaking through the current industry.</p><p>This is also the value of JD Health empowering doctors. Improving doctors' abilities through digital means can not only better attract excellent doctors into JD Health's ecosystem, but also bring a virtuous cycle to the entire ecosystem. This is also an ideal development \"path\" in the medical and health field in Internet plus.</p><p>In terms of industry empowerment, JD Health is promoting the sharing of medical and health information through its \"Healthy City\" strategy. Based on this, JD Health has also increased its cooperation with local governments and hospitals to create<a href=\"https://laohu8.com/S/300959\">Online and offline</a>An integrated healthcare service ecosystem. For example, in the first half of this year, JD Health partnered with the First Affiliated Hospital of Henan University of Traditional Chinese Medicine to build Henan's first TCM internet hospital, creating an \"innovative model\" for offline hospitals to improve their operational capabilities by building their own internet hospitals. Looking back over the past few years, JD Health has also reached strategic cooperation agreements with Yinchuan and Beihai to explore the regional implementation of the \"Internet plus Healthcare\" model.</p><p>At this point, JD Health's layout in the B-end market is gradually becoming clear. By penetrating more diverse scenarios, we can deeply explore the diverse needs of users; Technology empowers doctors, connecting high-quality medical resources while improving industry efficiency; Through cooperation with cities across the country, we will promote the overall implementation of medical informatization.</p><p>Looking at a longer timeframe, the multiplier effect brought about by ecosystem openness will gradually be reflected in JD Health.</p><p><b>/03 /</b></p><p><b>JD.com's \"genes\" behind the industry</b></p><p>JD Health is making unprecedented inroads into the medical industry to serve the real economy. This is inseparable from JD.com's long-standing \"physical\" DNA.</p><p>Similar to JD.com's digital transformation of the e-commerce industry, JD Health is transforming the medical and health industry in the same way. This is reflected in two aspects:</p><p>From a starting point perspective, whether it's JD.com or JD Health, digital technology is the starting point for empowering the industry. Looking at the entire internet industry, JD.com has consistently been one of the technology companies with the largest technological investment in China. Over the past four years, JD.com has invested nearly 60 billion yuan in R&D.</p><p>JD.com's technological DNA is also deeply imprinted on JD Health. For a considerable period of time, JD Health has been continuously investing in technological research and development to improve doctor efficiency and optimize user experience.</p><p>In the first half of 2021, JD Health continued to increase its R&D investment, focusing on improving user experience and creating digital and intelligent tools for doctors. Taking JD Home Doctor as an example, through cooperation with smart hardware, JD Home Doctor has \"implanted\" online consultations that originally needed to be completed through a mobile APP into a smart speaker that can summon services by voice, and launched the \"JD Home Doctor Filial Piety Edition\" which is more suitable for the elderly, breaking through the traditional interaction method of online consultation.</p><p>From the underlying logic, both sides are continuously creating social value in different ways. JD.com needs no further explanation. Through solid supply chain management, JD.com's image of \"speed, efficiency, and cost-effectiveness\" in the retail sector has become deeply ingrained in people's minds.</p><p>For JD Health, inclusive healthcare is its focus in creating social value. For example, in response to sudden disasters, JD Health has comprehensively upgraded its emergency response mechanism this year to ensure timely support for residents' health protection.</p><p>This mechanism also played an important role in the recent severe rainstorm disaster in Henan. During the severe rainstorm in Henan, JD Health immediately launched flood prevention and assistance operations, including launching a 24-hour free online consultation zone. At the same time, the company urgently established and dispatched an offline medical rescue team to conduct on-site diagnosis and treatment.</p><p>From a broader perspective, JD Health continuously empowers the medical industry and improves the overall efficiency of the industry through digital means, which is also fulfilling its social responsibility.</p><p>Of course, compared with the retail industry, the process of digitalization transforming the healthcare industry may be longer. However, this also means that once the transformation is completed, JD Health's commercial moat will be even more solid. Considering that healthcare itself is a huge market, as JD Health's healthcare ecosystem takes shape, it is not impossible to \"create another JD.com\".</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3cfc5f3c5c9987e1de0c5ad74e29feb3","relate_stocks":{"06618":"京东健康"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123728452","content_text":"「我们看见的不仅是一个海角，而是一个新的世界」。\n五百年前，历史学家巴若斯记录了他在抵达好望角时的感受：\n1488 年，巴若思乘坐葡萄牙航海家迪亚士率领的船队，从非洲西海岸南亚出发抵达这片海域时，他和所有人一样，当凝望着这狭长的岬角时，激动得说不出话来。\n在此前相当长的时间里，好望角都因海流相撞引起的滔天巨浪终年不息，被称为风暴角。五百年后，当我们创造出互联网，就像航海家绕过好望角发现新航路一般，给各个行业都打开了一个新世界的大门，互联网医疗也不例外。\n在互联网医疗的战场，一直处于多方竞争的环境中。从过去看，以医疗质量为核心的社会价值属性始终是医疗健康产业的第一性原理。而如今，京东健康以供应链卡位切入，承接更多元的医疗服务场景落地，最终在行业占据了一席之地。\n从财务数据看，京东健康仍然在延续过去的高增长。今年上半年，京东健康总收入为人民币136.4亿元，同比增长55.4%。在业务数据高速增长的同时，京东健康上半年毛利率连续两年同比下降超过1%。原因很简单，上半年公司为用户免费提供大量在线咨询、以及将优质商品持续平价销售以让利用户，经营策略可谓相当“接地气”。\n拉长周期看，不断提高的医疗服务质量，以及“接地气”的经营策略，正在让京东健康在互联网医疗的地位愈发稳固。\n/ 01 /\n仍在进化的医疗生态「压舱石」\n京东健康“以退为进”的策略，正在让其医疗生态迅速扩大。从财报看，京东健康医疗生态的扩张主要体现在三个层面：优质医疗资源持续做深、供应链优势进一步夯实，以及终端用户高速增长。\n在医疗资源端，为了更好地为用户提供在线医疗健康服务，京东健康加大了对优质医疗的开拓。截至2021年6月30日，京东健康互联网医院开设的专科中心已增至24个，吸纳自有和外部合作医生及医疗专家超过13万名。其中，不乏韩德民院士、胡大一教授、高思华教授、林江涛教授等知名医生。\n随着越来越多的全国学科带头人级别的专家和顶级名医的加入，京东健康进一步完善了互联网医疗健康服务体系。得益于此，京东健康在上半年日均在线咨询量超过16万，较2020年全年日均在线问诊量提升60%左右。\n而作为京东健康一直以来的优势项目，其供应链优势也在上半年得到进一步夯实。一方面，京东健康零售药房业务的SKU持续扩充。截至2021年6月30日，京东健康零售药房业务已有超过4000万个商品（SKU），较去年年底接近翻倍。\n另一方面，京东健康也在不断强化自身的履约能力。截至今年上半年，“京东药急送”已覆盖全国超过300个城市，为用户提供覆盖全时段的送药服务。同时，京东健康还通过数智化供应链能力助力线下小微企业降本增效。如今，京东健康-联盟大药房累计合作门店已超过500家，覆盖全国17个省级行政区。\n某种程度上说，持续丰富的医疗资源和不断夯实的供应链优势，正在成为京东健康整个医疗生态的“压舱石”。\n“压舱石”的持续进化，也为京东健康带来了用户端的高增长。截至2021年6月30日，京东健康过去12个月的年度活跃用户数量达到1.09亿，较2020年底的用户数净增加超过1880万。\n与此同时，京东健康2020年推出的家庭健康管理服务产品——京东家医，同样表现不俗。2021年上半年，京东健康的用户活跃占比达87%，上线至今用户数月平均环比增速220%。\n\n随着医疗生态的全面开花，也为京东健康后续的增长打下坚实基础。\n/ 02 /\n从“医疗+”到“医疗×”，\n数字化能力全面外溢\n在To C业务持续增长的同时，京东健康的To B服务也迎来了全面爆发。一个明显的现象是，京东健康正在加大与医疗健康产业链各个环节的合作，全面开放自己的数字化能力。\n\n从目前看，京东健康To B服务的落地，可以集中体现在医疗健康场景、医生服务和区域医疗信息化三个方面。\n在医疗健康场景方面，京东健康正在持续开拓更多元的服务场景。比如，公司将“京东家医”服务作为标准模块，与智能音箱、智能手环等智能医用可穿戴设备厂商开展合作，实现“京东家医”产品与智能硬件的结合。\n此外，在健康险场景上京东健康也有所突破。5月，京东健康联合复星联合健康、京东安联保险等多家保险公司，共同推出了管理型健康险服务——“家医保”。该产品以预防疾病、改善健康为核心目的，将健康险与京东健康的医疗服务、健康管理能力相结合，为家庭提供了一站式终身医疗健康服务和健康保障解决方案。\n多元化场景渗透，对京东健康的意义巨大。短期看，更多场景能够丰富京东健康的服务和产品类别。而拉长周期看，生态型公司的价值往往都取决于其所在生态的生产率，以及它们的贡献占比，而场景延伸正是提升生态贡献占比的重要途径。\n在医生服务端，京东健康通过为医生提供流量建设、智慧化线上工具、专属权益等服务，构建全场景的运营生态，不断拓展着为医生服务的能力。\n比如，为医生提供安全的执业环境。无论是对于互联网医院还是医生而言，职责的清晰以及个人风险防控是一个医生愿意上线互联网医院的根本所在。京东健康通过数据安全体系保护医生个人的信息安全，再通过线上诊疗中的流程风控、医责险的购置等规避在线诊疗风险。那么，在京东健康对医生赋能背后，我们应该如何理解其意义？\n在互联网+医疗健康领域，生产力水平的提升，很大程度上是依靠互联网医生群体完成的。换句话说，如何不断提升互联网+医疗健康之于医生的价值，更好地辅助医生开展临床科研和诊疗活动，自然成为当前行业破局的关键。\n这也是京东健康赋能医生的价值所在，通过数字化手段提升医生能力，不仅能更好吸引优秀医生进入京东健康的生态系统中，更能为整个生态系统带来良性循环。这也不失为互联网+医疗健康领域里一种理想的发展“路径”。\n在产业赋能看，京东健康正在以“健康城市”战略推进医疗健康信息互通共享。基于此，京东健康也加大了与地方政府、医院合作，打造线上线下一体化医疗健康服务生态。比如，今年上半年，京东健康与河南中医药大学第一附属医院合作搭建了河南首家中医互联网医院，打造线下医院自建互联网医院提升运营能力的“创新样本”。回顾过去几年，京东健康也与银川、北海多地达成战略合作，探索“互联网+医疗健康”模式在区域化的落地。\n至此，京东健康在B端的布局逐渐清晰。通过更多元的场景渗透，深度挖掘用户的多样化需求；科技赋能医生，在连接优质医疗资源的同时，提升产业效率；通过与各地城市的合作，推动医疗信息化的整体落地。\n拉长周期看，生态开放带来的乘数效应，也将逐渐在京东健康上得到体现。\n/ 03 /\n深入产业背后的京东“基因”\n京东健康正在史无前例地深入医疗产业之中，服务实体经济。这背后离不开京东这家公司一直以来的“实体”基因。\n与京东集团通过数字化改造电商行业类似，京东健康正在以同样的路径改造着医疗健康产业。体现在两个层面：\n从起点看，无论是京东，还是京东健康，数字化技术都是其赋能行业的起点。放眼整个互联网行业，京东一直都是国内技术投入最大的科技企业之一。过去4年，京东体系四年累计研发费用投入近600亿元。\n京东的技术基因，也深深烙在了京东健康这家公司上。在过去相当长时间里，京东健康都通过不断的技术研发投入，提升医生效率、优化用户体验。\n2021上半年，京东健康持续加大研发投入，并重点用于用户体验提升和医生数智化工具的打造。以京东家医为例，京东家医通过与智能硬件的合作，将原本需要通过手机APP完成的在线咨询，“植入”了可语音唤起服务的智能音箱中，推出更适合老年人使用的“京东家医孝心版”，突破了传统在线咨询的交互方式。\n从底层逻辑看，双方都在以不同的方式，持续创造着社会价值。京东自然不必多说。通过扎实的供应链管理，京东在零售领域“多快好省”的形象已经深入人心。\n对京东健康来说，普惠医疗就是其创造社会价值的着力点。比如，针对突发灾害事件，京东健康今年全面升级应急回应机制，以确保第一时间支持居民健康保障。\n这样的机制，也在本次河南特大暴雨灾害发挥了重要作用。在河南特大暴雨灾害中，京东健康第一时间展开防汛援助行动，包括上线24小时免费在线咨询专区。与同此时，公司紧急组建并派出线下医疗救援队，开展现场诊疗。\n站在更大维度上去看，京东健康通过数字化手段，持续赋能医疗产业，提升行业整体效率，又何尝不是在践行社会责任呢？\n固然，与零售行业相比，数字化对医疗健康行业的改造进程可能更为漫长。但这也意味着，一旦改造完成，京东健康的商业护城河也更为牢固。考虑到医疗健康本身是一个巨大市场，随着京东健康的医疗健康生态日益成型，“再造一个京东”也未尝没有可能。","news_type":1,"symbols_score_info":{"06618":0.9}},"isVote":1,"tweetType":1,"viewCount":4984,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801885858,"gmtCreate":1627508922774,"gmtModify":1703491180130,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583528354923579","idStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801885858","repostId":"2154992231","repostType":2,"repost":{"id":"2154992231","kind":"news","pubTimestamp":1627378800,"share":"https://ttm.financial/m/news/2154992231?lang=en_US&edition=fundamental","pubTime":"2021-07-27 17:40","market":"hk","language":"zh","title":"Forbes China Interview with Xia Yu, Chairman of Akeso Biologics: Leaning Towards a Tiger's Den","url":"https://stock-news.laohu8.com/highlight/detail?id=2154992231","media":"财经自媒体","summary":"　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”　　今年4月，康方生物公布了上市后的首份年度成绩单。","content":"<p><html><body><div><p cms-style=\"font-L\">Source: Forbes</p><p><p cms-style=\"font-L\">In the field of pharmaceutical innovation,<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>、<a href=\"https://laohu8.com/S/JNJ\">Johnson and Johnson</a>、<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>、<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>With numerous international giants emerging, it may not be feasible to hone one's skills in ten years.</p><p><p cms-style=\"font-L\">Xia Yu, founder and chairman of Akeso Biopharma, told Forbes China:<span><a href=\"https://laohu8.com/S/600056\">Chinese medicine</a></span><span></span>The true rise of innovation must rely on its own strength, cultivate an innovation atmosphere, build an innovation system, and achieve breakthroughs in innovation achievements. From the perspective of the business model of global industry development, there is no problem with the model of buying, buying, buying, but leading giants in the pharmaceutical industry such as Pfizer, Johnson & Johnson, AstraZeneca, and Novo Nordisk, pharmaceutical companies with a place in the world, should China appear? \"</p><p><p cms-style=\"font-L\">\"China should emerge,\" Xia Yu said firmly, adding that these companies' own R&D and innovation capabilities are key to becoming world-class leaders.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/324/w550h574/20210727/9053-eb59dd1acbf005315f9f014538a392da.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Xia Yu, founder and chairman of Akeso Biotech Co., Ltd.</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">However, where should Chinese pharmaceutical companies that can compete with or even surpass giants place their hopes?</p><p><p cms-style=\"font-L\">In April of this year, Akeso Biotech released its first annual performance report since its listing. The announcement shows that as of the end of 2020, Akeso Biotech's other income and gains exceeded 100 million yuan; R&D investment reached 764.5 million yuan.</p><p><p cms-style=\"font-L\">After ten years of entrepreneurship, Akeso Biologics has finally pioneered a pioneering track in the research and development of original Chinese antibody drugs: among more than 20 drugs under development, 6 are world-first or leading bispecific antibodies, the research and development progress of many cutting-edge target drug candidates is world-leading, more than 20 clinical research projects are in Phase II clinical trials and beyond, and the core world-first bispecific antibodies are about to be launched... A Chinese biotechnology company that has truly gone global through self-development has quietly risen.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/80/w550h330/20210727/0264-3242e677075ee7bd62b8859c7068fc7c.jpg\"/><span></span></div></div><p cms-style=\"font-L\">World's first bispecific antibody cadonilimab</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The buy-buy-buy model can't buy China's Pfizer or China's Johnson & Johnson.</font></p><p><p cms-style=\"font-L\">More than a decade ago, Xia Yu, who had built a comfortable and superior life in a foreign land, returned to China and had the idea of starting a business amidst the bustling crowds of Beijing. As a Chinese person, the first question that comes to Xia Yu's mind is whether China needs original new drugs. Are Chinese people only allowed to use outdated foreign medicines from ten years ago for decades?</p><p><p cms-style=\"font-L\">“Actually, if I were doing the same thing (pharmaceutical research and development) in the United States, I would very likely stop after a certain stage of research and development,” Xia Yu further said. “Because I myself know very well that the investment in production, commercialization, and even clinical trials after research and development is just too huge. But today, with the development of the domestic pharmaceutical industry, whether from the perspective of capital market development or industrial policy support, China actually has the possibility of conquering the global industry high ground.”</p><p><p cms-style=\"font-L\">Of course, a natural shortcoming for Chinese pharmaceutical companies in participating in global competition is their late start and relatively backward overall development level of the industry. \"But the gap does not mean that we cannot achieve world leadership in certain fields, directions, or stages.\"</p><p><p cms-style=\"font-L\">Xia Yu is well aware that there are two paths to choose from when entering the pharmaceutical industry. One path is original research and development, which involves using the company's own internal research and development capabilities to obtain competitive innovative drugs. Another approach is to improve the company's R&D pipeline through external introductions.</p><p><p cms-style=\"font-L\">Ten years ago, the research and development of new drugs in China's pharmaceutical industry was \"poor and white\". Xia Yu still chose the path of originality.</p><p><p cms-style=\"font-L\">Even in recent years, the return of a number of overseas returnee entrepreneurs has actually driven the return of individual advanced technologies. However, Xia Yu has been thinking and practicing how to drive the overall pharmaceutical industry to cultivate and develop in China, and how to establish a truly advanced R&D system in China. Without being in a hurry, or even sacrificing the opportunity to produce advanced products, Xia Yu led Akeso Biotech to invest huge energy in creating an integrated R&D system internally from the very beginning of its establishment.</p><p><p cms-style=\"font-L\">Only under such an innovative R&D system, with this willingness and ideal to grow, from the source of R&D to industrialization, will China's Pfizer and China's Johnson & Johnson emerge in the future.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/40/w550h290/20210727/55da-1b43fa5d55b5db075d491294cb78bfd6.png\"/><span></span></div></div><p cms-style=\"font-L\">Exterior view of Akeso Biotech's Guangzhou base</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">Since its establishment in 2012, Akeso Biologics has focused on developing the world's most cutting-edge tumor immunotherapy antibodies, starting with the most advanced original scientific research and innovation, all the way to the layout of production, commercialization and clinical trials. Currently, Akeso has developed more than 20 innovative drug candidates, of which 13 innovative antibody drugs are in the clinical research stage.</p><p><p cms-style=\"font-L\">\"Actually, not developing original new drugs is an understandable business model. The only problem I think is that this matter has become a red ocean, and anything that enters a red ocean will be terrifying.\" In China, an industrial reality facing drug regulation is that even in 2016, the total R&D investment of pharmaceutical companies nationwide was still less than that of the world's largest pharmaceutical company.</p><p><p cms-style=\"font-L\">\"On the one hand, we need to create fertile ground for industrial development; on the other hand, we must establish a competitive mechanism based on survival of the fittest. The current pharmaceutical giants in the United States are also the result of survival of the fittest after industrial development and market competition. A similar scenario is expected to emerge in China in the future,\" Xia Yu said.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The stark contrast between ice and fire: the double-edged sword of capital.</font></p><p><p cms-style=\"font-L\">Even in the past two years, with the reform of the Hong Kong Stock Exchange's new share listing system and the introduction of the registration system of the Science and Technology Innovation Board, new financing opportunities and more diverse choices have been provided to pharmaceutical companies with different market orientations, different investor compositions, and different entry and exit mechanisms. What remains unchanged is that the business model for starting a business must be able to withstand the test of capital preservation and appreciation capabilities.</p><p><p cms-style=\"font-L\">Xia Yu recalled that in the early stages of starting a business, if we really couldn't get the financial support of the capital market, we might have survived in other ways, but it is certain that it would have been far from possible to achieve the rapid development we have now. A significant role of capital is to help accelerate the development of enterprises, allowing them to focus more on building robust innovative competitiveness in a competitive environment.</p><p><p cms-style=\"font-L\">　　<a href=\"https://laohu8.com/S/V03.SI\">Startup company</a>The business model chosen at each stage of development will be reflected differently at different stages of development.</p><p><p cms-style=\"font-L\">At the beginning of the business in 2012, drug innovation companies were not as sought after in the capital market as they are now. In order to survive and continue to develop, at the end of 2015, Xia Yu decided to license an innovative product from Akeso Biotech to a giant.<a href=\"https://laohu8.com/S/MRK\">Merck</a>。 \"I think from a business model perspective, at that moment it was definitely a decision that was beneficial to the company's long-term development and supported our long-term development.\" On the other hand, this is the first time that an innovative antibody drug independently developed by a Chinese domestic company has been licensed to a TOP5 international pharmaceutical giant. It has also become one of the landmark events for China's innovative drug industry to truly go international and gain international recognition, and it has also allowed Akeso Biotech to step onto the world stage of drug innovation for the first time.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/117/w550h367/20210727/b886-3bb61d586babf8c3cb5f2b87668503b0.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Production workshop</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">\"Actually, I understand the capital market very well. In the early stages of our business, we spent a lot of time developing the platform, which is why we have achieved many results on the platform now. At Kangfang, while efficiently advancing the clinical development of our existing pipeline, we will focus more on cutting-edge target drugs in product development. This is because we already have a good product foundation and development experience, and have also gained the recognition of investors.\" But if I took investors' money to do 10 years of innovative research and development without any products at all, which investor would agree?</p><p><p cms-style=\"font-L\">If the birth of a new drug is a relay race for various companies in the industry chain, Xia Yu's determination is a marathon.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">From studying abroad alone to returning to China to start a business with a market value of 50 billion yuan</font></p><p><p cms-style=\"font-L\">A noteworthy phenomenon is that nearly 20% of the founders of emerging innovative companies in the pharmaceutical industry are women. Having accumulated extensive experience in biopharmaceutical research and development, Xia Yu, as an antibody drug research and development expert, decided to return to China to start a business and found Akeso Biotech with three other returnees. Xia Yu, as chairman, is the only woman in the management team.</p><p><p cms-style=\"font-L\">Xia Yu said, \"Women are more tolerant, more resilient, and more dedicated and persistent in doing something.\"</p><p><p cms-style=\"font-L\">\"But all perfection is relative, and there is no perfect persona in entrepreneurship.\"</p><p><p cms-style=\"font-L\">Just as Xia Yu initially decided to return to China to start a business, even with the support of her daughter's family, she still had to face the incomprehension of those around her. As a mother, shouldn't she be there for her daughter wholeheartedly during this crucial stage of her growth? As a woman, why would she still pursue a so-called career when she is living a comfortable life in middle age?</p><p><p cms-style=\"font-L\">With an incomprehensible sting, Xia Yu and her daughter transformed and grew together. Now, her daughter says that her mother is the person she admires most.</p><p><p cms-style=\"font-L\">At this point, more than ten years had passed since Xia Yu single-handedly founded Akeso Biotech.</p><p><p cms-style=\"font-L\">Following Akeso Biologics' official listing on the Hong Kong Stock Exchange in 2020, its total market capitalization has now reached HK$55 billion.</p><p><p cms-style=\"font-L\">Looking back on her youth, Xia Yu, who was a top student, said, \"I went abroad right after graduating from university. At that time, I relied entirely on myself to get a scholarship and ran abroad with only a few dollars in my pocket. When I went abroad, I found that it was a world of difference from China. I was very nervous at the time and didn't know what would happen next.\"</p><p><p cms-style=\"font-L\">Over the next 20 years, Xia Yu worked at Sino-American Crown Biotechnology,<a href=\"https://laohu8.com/S/PDLI\">PDL BioPharma</a>He held management positions at multinational pharmaceutical companies such as Bayer and CrownBio in Germany, and after completing postdoctoral research at the University of Glasgow in the UK, he conducted scientific research at the University of Louisville School of Medicine in the United States. During his tenure as Senior Vice President of Sino-American Crown Biotechnology, he played a decisive role in formulating and executing the company's strategy and establishing a joint venture with Pfizer.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/462/w550h712/20210727/7570-3cd7c1d54dc532007a1a67b35d002611.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Dr. Xia Yu</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">In the founding team, Xia Yu is responsible for the company's overall strategic planning, business and scientific development direction. Xia Yu said, \"What is needed at the crucial moment for enterprise development is the courage to make decisions and to bear the pressure and responsibility of decision-making. It truly tests the leader's foresight and control over the enterprise's development.\"</p><p><p cms-style=\"font-L\">After achieving fruitful results in the \"original R&D route\" campaign, Xia Yu is now leading Akeso biotech to face the next challenge: product commercialization, moving from biotech to biopharma.</p><p><p cms-style=\"font-L\">According to Xia Yu, \"Some companies may have made it very clear from the very beginning that they are not involved in production or future commercialization, and just do what they are good at, which is also a good business model. But for some companies, such as Akeso Biotech, I don't actually set limits for the future. As long as conditions permit and it aligns with the company's development strategy, we will promote it.\"</p><p><p cms-style=\"font-L\">The first condition, for example, is that I have enough talent and ability to carry out both production and commercialization, which requires a larger corporate development goal to drive it. In addition, as a founder, I also need to have this ideal, which I think is very important. Because the further we reach the production and commercialization stage, the greater the uncontrollability, and courage is essential.</p><p><p cms-style=\"font-L\">Knowing there are tigers in the mountains, they still venture into the tiger's den. This is Xia Yu's perseverance and resilience.</p><p><div><div><img src=\"\"/></div><div>Massive amounts of information and accurate interpretation are available here.<a href=\"https://laohu8.com/S/SINA\">Sina</a>Financial APP</div></div>Editor: Liu Wanli SF014</p><p></div></body></html></p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forbes China Interview with Xia Yu, Chairman of Akeso Biologics: Leaning Towards a Tiger's Den</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForbes China Interview with Xia Yu, Chairman of Akeso Biologics: Leaning Towards a Tiger's Den\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">财经自媒体</strong><span class=\"h-time small\">2021-07-27 17:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><div><p cms-style=\"font-L\">Source: Forbes</p><p><p cms-style=\"font-L\">In the field of pharmaceutical innovation,<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>、<a href=\"https://laohu8.com/S/JNJ\">Johnson and Johnson</a>、<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>、<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>With numerous international giants emerging, it may not be feasible to hone one's skills in ten years.</p><p><p cms-style=\"font-L\">Xia Yu, founder and chairman of Akeso Biopharma, told Forbes China:<span><a href=\"https://laohu8.com/S/600056\">Chinese medicine</a></span><span></span>The true rise of innovation must rely on its own strength, cultivate an innovation atmosphere, build an innovation system, and achieve breakthroughs in innovation achievements. From the perspective of the business model of global industry development, there is no problem with the model of buying, buying, buying, but leading giants in the pharmaceutical industry such as Pfizer, Johnson & Johnson, AstraZeneca, and Novo Nordisk, pharmaceutical companies with a place in the world, should China appear? \"</p><p><p cms-style=\"font-L\">\"China should emerge,\" Xia Yu said firmly, adding that these companies' own R&D and innovation capabilities are key to becoming world-class leaders.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/324/w550h574/20210727/9053-eb59dd1acbf005315f9f014538a392da.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Xia Yu, founder and chairman of Akeso Biotech Co., Ltd.</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">However, where should Chinese pharmaceutical companies that can compete with or even surpass giants place their hopes?</p><p><p cms-style=\"font-L\">In April of this year, Akeso Biotech released its first annual performance report since its listing. The announcement shows that as of the end of 2020, Akeso Biotech's other income and gains exceeded 100 million yuan; R&D investment reached 764.5 million yuan.</p><p><p cms-style=\"font-L\">After ten years of entrepreneurship, Akeso Biologics has finally pioneered a pioneering track in the research and development of original Chinese antibody drugs: among more than 20 drugs under development, 6 are world-first or leading bispecific antibodies, the research and development progress of many cutting-edge target drug candidates is world-leading, more than 20 clinical research projects are in Phase II clinical trials and beyond, and the core world-first bispecific antibodies are about to be launched... A Chinese biotechnology company that has truly gone global through self-development has quietly risen.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/80/w550h330/20210727/0264-3242e677075ee7bd62b8859c7068fc7c.jpg\"/><span></span></div></div><p cms-style=\"font-L\">World's first bispecific antibody cadonilimab</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The buy-buy-buy model can't buy China's Pfizer or China's Johnson & Johnson.</font></p><p><p cms-style=\"font-L\">More than a decade ago, Xia Yu, who had built a comfortable and superior life in a foreign land, returned to China and had the idea of starting a business amidst the bustling crowds of Beijing. As a Chinese person, the first question that comes to Xia Yu's mind is whether China needs original new drugs. Are Chinese people only allowed to use outdated foreign medicines from ten years ago for decades?</p><p><p cms-style=\"font-L\">“Actually, if I were doing the same thing (pharmaceutical research and development) in the United States, I would very likely stop after a certain stage of research and development,” Xia Yu further said. “Because I myself know very well that the investment in production, commercialization, and even clinical trials after research and development is just too huge. But today, with the development of the domestic pharmaceutical industry, whether from the perspective of capital market development or industrial policy support, China actually has the possibility of conquering the global industry high ground.”</p><p><p cms-style=\"font-L\">Of course, a natural shortcoming for Chinese pharmaceutical companies in participating in global competition is their late start and relatively backward overall development level of the industry. \"But the gap does not mean that we cannot achieve world leadership in certain fields, directions, or stages.\"</p><p><p cms-style=\"font-L\">Xia Yu is well aware that there are two paths to choose from when entering the pharmaceutical industry. One path is original research and development, which involves using the company's own internal research and development capabilities to obtain competitive innovative drugs. Another approach is to improve the company's R&D pipeline through external introductions.</p><p><p cms-style=\"font-L\">Ten years ago, the research and development of new drugs in China's pharmaceutical industry was \"poor and white\". Xia Yu still chose the path of originality.</p><p><p cms-style=\"font-L\">Even in recent years, the return of a number of overseas returnee entrepreneurs has actually driven the return of individual advanced technologies. However, Xia Yu has been thinking and practicing how to drive the overall pharmaceutical industry to cultivate and develop in China, and how to establish a truly advanced R&D system in China. Without being in a hurry, or even sacrificing the opportunity to produce advanced products, Xia Yu led Akeso Biotech to invest huge energy in creating an integrated R&D system internally from the very beginning of its establishment.</p><p><p cms-style=\"font-L\">Only under such an innovative R&D system, with this willingness and ideal to grow, from the source of R&D to industrialization, will China's Pfizer and China's Johnson & Johnson emerge in the future.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/40/w550h290/20210727/55da-1b43fa5d55b5db075d491294cb78bfd6.png\"/><span></span></div></div><p cms-style=\"font-L\">Exterior view of Akeso Biotech's Guangzhou base</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">Since its establishment in 2012, Akeso Biologics has focused on developing the world's most cutting-edge tumor immunotherapy antibodies, starting with the most advanced original scientific research and innovation, all the way to the layout of production, commercialization and clinical trials. Currently, Akeso has developed more than 20 innovative drug candidates, of which 13 innovative antibody drugs are in the clinical research stage.</p><p><p cms-style=\"font-L\">\"Actually, not developing original new drugs is an understandable business model. The only problem I think is that this matter has become a red ocean, and anything that enters a red ocean will be terrifying.\" In China, an industrial reality facing drug regulation is that even in 2016, the total R&D investment of pharmaceutical companies nationwide was still less than that of the world's largest pharmaceutical company.</p><p><p cms-style=\"font-L\">\"On the one hand, we need to create fertile ground for industrial development; on the other hand, we must establish a competitive mechanism based on survival of the fittest. The current pharmaceutical giants in the United States are also the result of survival of the fittest after industrial development and market competition. A similar scenario is expected to emerge in China in the future,\" Xia Yu said.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The stark contrast between ice and fire: the double-edged sword of capital.</font></p><p><p cms-style=\"font-L\">Even in the past two years, with the reform of the Hong Kong Stock Exchange's new share listing system and the introduction of the registration system of the Science and Technology Innovation Board, new financing opportunities and more diverse choices have been provided to pharmaceutical companies with different market orientations, different investor compositions, and different entry and exit mechanisms. What remains unchanged is that the business model for starting a business must be able to withstand the test of capital preservation and appreciation capabilities.</p><p><p cms-style=\"font-L\">Xia Yu recalled that in the early stages of starting a business, if we really couldn't get the financial support of the capital market, we might have survived in other ways, but it is certain that it would have been far from possible to achieve the rapid development we have now. A significant role of capital is to help accelerate the development of enterprises, allowing them to focus more on building robust innovative competitiveness in a competitive environment.</p><p><p cms-style=\"font-L\">　　<a href=\"https://laohu8.com/S/V03.SI\">Startup company</a>The business model chosen at each stage of development will be reflected differently at different stages of development.</p><p><p cms-style=\"font-L\">At the beginning of the business in 2012, drug innovation companies were not as sought after in the capital market as they are now. In order to survive and continue to develop, at the end of 2015, Xia Yu decided to license an innovative product from Akeso Biotech to a giant.<a href=\"https://laohu8.com/S/MRK\">Merck</a>。 \"I think from a business model perspective, at that moment it was definitely a decision that was beneficial to the company's long-term development and supported our long-term development.\" On the other hand, this is the first time that an innovative antibody drug independently developed by a Chinese domestic company has been licensed to a TOP5 international pharmaceutical giant. It has also become one of the landmark events for China's innovative drug industry to truly go international and gain international recognition, and it has also allowed Akeso Biotech to step onto the world stage of drug innovation for the first time.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/117/w550h367/20210727/b886-3bb61d586babf8c3cb5f2b87668503b0.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Production workshop</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">\"Actually, I understand the capital market very well. In the early stages of our business, we spent a lot of time developing the platform, which is why we have achieved many results on the platform now. At Kangfang, while efficiently advancing the clinical development of our existing pipeline, we will focus more on cutting-edge target drugs in product development. This is because we already have a good product foundation and development experience, and have also gained the recognition of investors.\" But if I took investors' money to do 10 years of innovative research and development without any products at all, which investor would agree?</p><p><p cms-style=\"font-L\">If the birth of a new drug is a relay race for various companies in the industry chain, Xia Yu's determination is a marathon.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">From studying abroad alone to returning to China to start a business with a market value of 50 billion yuan</font></p><p><p cms-style=\"font-L\">A noteworthy phenomenon is that nearly 20% of the founders of emerging innovative companies in the pharmaceutical industry are women. Having accumulated extensive experience in biopharmaceutical research and development, Xia Yu, as an antibody drug research and development expert, decided to return to China to start a business and found Akeso Biotech with three other returnees. Xia Yu, as chairman, is the only woman in the management team.</p><p><p cms-style=\"font-L\">Xia Yu said, \"Women are more tolerant, more resilient, and more dedicated and persistent in doing something.\"</p><p><p cms-style=\"font-L\">\"But all perfection is relative, and there is no perfect persona in entrepreneurship.\"</p><p><p cms-style=\"font-L\">Just as Xia Yu initially decided to return to China to start a business, even with the support of her daughter's family, she still had to face the incomprehension of those around her. As a mother, shouldn't she be there for her daughter wholeheartedly during this crucial stage of her growth? As a woman, why would she still pursue a so-called career when she is living a comfortable life in middle age?</p><p><p cms-style=\"font-L\">With an incomprehensible sting, Xia Yu and her daughter transformed and grew together. Now, her daughter says that her mother is the person she admires most.</p><p><p cms-style=\"font-L\">At this point, more than ten years had passed since Xia Yu single-handedly founded Akeso Biotech.</p><p><p cms-style=\"font-L\">Following Akeso Biologics' official listing on the Hong Kong Stock Exchange in 2020, its total market capitalization has now reached HK$55 billion.</p><p><p cms-style=\"font-L\">Looking back on her youth, Xia Yu, who was a top student, said, \"I went abroad right after graduating from university. At that time, I relied entirely on myself to get a scholarship and ran abroad with only a few dollars in my pocket. When I went abroad, I found that it was a world of difference from China. I was very nervous at the time and didn't know what would happen next.\"</p><p><p cms-style=\"font-L\">Over the next 20 years, Xia Yu worked at Sino-American Crown Biotechnology,<a href=\"https://laohu8.com/S/PDLI\">PDL BioPharma</a>He held management positions at multinational pharmaceutical companies such as Bayer and CrownBio in Germany, and after completing postdoctoral research at the University of Glasgow in the UK, he conducted scientific research at the University of Louisville School of Medicine in the United States. During his tenure as Senior Vice President of Sino-American Crown Biotechnology, he played a decisive role in formulating and executing the company's strategy and establishing a joint venture with Pfizer.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/462/w550h712/20210727/7570-3cd7c1d54dc532007a1a67b35d002611.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Dr. Xia Yu</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">In the founding team, Xia Yu is responsible for the company's overall strategic planning, business and scientific development direction. Xia Yu said, \"What is needed at the crucial moment for enterprise development is the courage to make decisions and to bear the pressure and responsibility of decision-making. It truly tests the leader's foresight and control over the enterprise's development.\"</p><p><p cms-style=\"font-L\">After achieving fruitful results in the \"original R&D route\" campaign, Xia Yu is now leading Akeso biotech to face the next challenge: product commercialization, moving from biotech to biopharma.</p><p><p cms-style=\"font-L\">According to Xia Yu, \"Some companies may have made it very clear from the very beginning that they are not involved in production or future commercialization, and just do what they are good at, which is also a good business model. But for some companies, such as Akeso Biotech, I don't actually set limits for the future. As long as conditions permit and it aligns with the company's development strategy, we will promote it.\"</p><p><p cms-style=\"font-L\">The first condition, for example, is that I have enough talent and ability to carry out both production and commercialization, which requires a larger corporate development goal to drive it. In addition, as a founder, I also need to have this ideal, which I think is very important. Because the further we reach the production and commercialization stage, the greater the uncontrollability, and courage is essential.</p><p><p cms-style=\"font-L\">Knowing there are tigers in the mountains, they still venture into the tiger's den. This is Xia Yu's perseverance and resilience.</p><p><div><div><img src=\"\"/></div><div>Massive amounts of information and accurate interpretation are available here.<a href=\"https://laohu8.com/S/SINA\">Sina</a>Financial APP</div></div>Editor: Liu Wanli SF014</p><p></div></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://finance.sina.com.cn/chanjing/cyxw/2021-07-27/doc-ikqcfnca9352486.shtml\">财经自媒体</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","relate_stocks":{"09926":"康方生物"},"source_url":"https://finance.sina.com.cn/chanjing/cyxw/2021-07-27/doc-ikqcfnca9352486.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2154992231","content_text":"来源：福布斯\n　　医药创新这个赛道，辉瑞、强生、阿斯利康、诺和诺德等国际巨头林立，十年磨一剑也未必可行。\n　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”\n　　“中国应该出现。”夏瑜很坚定，而这些企业自身的研发创新能力是企业成为世界级领导者的关键。\n\n\n\n　　康方生物有限公司创始人、董事长夏瑜\n　　图片来源：DR\n　　只是，能与巨头比肩甚至超越巨头的中国医药企业，应该把希望寄托于哪里？\n　　今年4月，康方生物公布了上市后的首份年度成绩单。公告显示，截至2020年底，康方生物其他收入及收益超1亿元；研发投入达到7.645亿元。\n　　创业十年，康方生物终于开拓出一条中国原创抗体药物研发的先行者赛道：20多款在研药物中，6款全球首创或进度领先的双特异性抗体，多款最前沿靶点候选药物研发进度全球领先，超过20个临床研究项目在临床II期及往后阶段，核心全球首创双抗即将上市……一家实打实通过自我研发走出国门的中国生物科技公司悄然崛起。\n\n\n\n　　全球首创双抗cadonilimab\n　　图片来源：DR\n　　买买买模式，买不来中国的辉瑞、中国的强生\n　　十几年前，在异国他乡已打拼出安逸优越生活的夏瑜回国，在北京熙熙攘攘的人群中，冒出创业的念头。作为一名中国人，夏瑜首先想到的问题是，中国是不是需要原创新药？中国人难道只能数十年如一日地用国外十年前的过时药？\n　　“其实，如果我在美国做同样的事情（医药研发），我很有可能做到一个研发某个阶段就不做了。”夏瑜进一步表示：“因为我自己也很清楚，研发后的生产和商业化，甚至临床实验的投入实在太巨大了。但时至今日，随着国内医药行业的发展，无论是从资本市场发展还是产业政策的支持来看，中国其实已经拥有了去攻占全球行业高地的可能。”\n　　当然，参与全球竞争，对于中国医药企业来说，一个天然短板是起步晚、行业整体发展水平相对落后。“但有差距并不代表我们自己在某一些领域、某一些方向、某一些阶段上，就没有办法做到世界领先。”\n　　夏瑜很清楚，踏入医药行业创业有两条路可以选，一条路是原创研发，利用公司自己内部的研发实力获得具有竞争力的创新药；另一条路则是通过外部引进的方式来完善公司的研发管线。\n　　在十年前，当时中国医药行业的新药研究和开发可谓“一穷二白”。夏瑜还是选择了原创的路。\n　　即便近年来，随着一批海归创业者的回归，事实上带动了个体先进技术的回归。但如何带动整体医药行业在中国去深耕建设，如何在中国建立真正先进的研发体系，夏瑜一直在思考与实践。没有急于一时，甚至是牺牲了生产先进产品的时机，夏瑜带领康方生物选择在创立之初，就投入巨大精力，在内部创建一体化的研发体系。\n　　只有在这样的创新研发体系下，具有这种意愿和理想去成长，从研发源头一直做到产业化，未来中国的辉瑞、中国的强生才会出现。\n\n\n\n　　康方生物广州基地外景\n　　图片来源：DR\n　　2012年成立至今，康方生物从最高端的源头科研创新入手，一直到生产、商业化和临床各产业阶段布局，专注开发全球最前沿的肿瘤免疫治疗抗体。目前，康方生物已经开发了超过20个创新候选药物，其中13款创新抗体新药处于临床研究阶段。\n　　“其实不做原创新药也是无可厚非的一种商业模式。唯一我认为出问题的地方是，这个事情变成了红海，而任何事情走入红海就会很可怕。”在中国，药品监管面临的一个产业现实是，即使到了2016年，全国制药企业研发投入总和仍不及全球最大制药企业一家。\n　　“一方面要形成培育产业发展的土壤，另一方面一定要建立优胜劣汰的竞争机制。美国现在的医药巨头，也是经历了产业发展和市场竞争后优胜劣汰的结果。在中国，未来也要出现这样的景象。”夏瑜说。\n　　冰火两重天，资本双刃剑\n　　即便近两年间，随着港交所新股上市制度改革及科创板注册制的推出，给面向市场不同、投资人构成不同、进退出机制考量不同的医药企业，提供了全新的融资机会和更多元的选择。不变的是，创业的商业模式都要能经得起资本保值增值能力的考验。\n　　夏瑜回顾，在创业初期，如果我们当时真的是得不到资本市场的资金支持，可能也会通过其它方式存活下来，但是可以肯定的是，远不可能实现现在的飞速发展。资本其实很大的一个作用是助力，加快企业的发展速度，让企业在竞争的环境中可以更加专心地构建资深的创新竞争力。”\n　　创业公司在每一个发展阶段所选择的商业模式在不同的发展阶段会有不同的体现。\n　　在创业之初2012年，药物创新企业在资本市场并不像现在这样备受追捧。为了生存和继续发展，2015年底，夏瑜决定将康方生物的一个创新产品授权给巨头默沙东。“我觉得从商业模式来讲，在那个时刻一定是一个利于公司长期发展的决定，支撑了我们走向长期发展。”另一方面，这是中国第一款本土企业自主研发的创新抗体药物授权给国际TOP5的制药巨头，也成为中国创新药物产业真正走向国际，并受到国际认可的一个标志性事件之一，也让康方生物在首次登上了药物创新的世界舞台。\n\n\n\n　　生产车间\n　　图片来源：DR\n　　“其实我很理解资本市场。在创业前期我们花了大量的时间做平台的开发，所以才有现在平台上很多的成果收获。时下的康方，我们在高效推进现有管线的临床发展的同时，在产品开发会更聚焦世界前沿的靶点药物。因为我们已经有了很好的产品基础、开发经验，也获得了投资人的认可。但如果我在什么产品都没有的情况下，拿着投资人的钱去做10年的创新研发，试问哪个投资人能答应？”\n　　如果说一种新药的诞生是产业链上各个公司的接力赛，夏瑜决心做的是一场马拉松。\n　　从只身海外求学到归国创业市值500亿\n　　一个值得关注的现象是，在医药行业崭露头角的创新公司中，近20%的创始人是女性。积累了资深的生物药物研究开发经历，作为抗体药物研发专家，夏瑜决定归国创业，与其他3名海归人士创立康方生物。夏瑜作为董事长，是管理团队中唯一一名女性。\n　　夏瑜说：“女性更包容，女性更有韧劲，对一件事情的执着和坚持。”\n　　“但是任何的完美都是相对的，创业没有完美人设。”\n　　就像夏瑜最初决定回国创业，即便得到了女儿家人的支持，仍要面对周遭的不解。已为人母，在女儿成长的关键阶段难道不应该全身心陪伴？作为一名女性，为什么在生活舒适的中年还要再去折腾所谓的事业？\n　　带着不被理解的刺痛，夏瑜和女儿一起蜕变、成长。如今，女儿说，妈妈是自己最崇拜的人。\n　　此时，距离夏瑜一腔孤勇创立康方生物已逾十年。\n　　继2020年康方生物在港交所正式挂牌上市，如今总市值一度冲击550亿港元。\n　　回顾曾经的青春岁月，学霸出身的夏瑜说，“大学一毕业我就出国了。那个时候完全是靠自己拿到一份奖学金，都没揣几块钱就跑出国门，到国外一看跟国内真的是天壤之别。当时很忐忑，不知道接下来会怎么样。”\n　　此后20年间，夏瑜在中美冠科生物、PDL BioPharma、德国拜耳、CrownBio等跨国制药公司担任管理职务，并在英国格拉斯哥大学完成博士后研究工作后，于美国路易斯维尔大学医学院进行科学研究；在担任中美冠科生物技术高级副总裁期间，为公司制定和执行战略以及与辉瑞建立合资企业方面发挥了决定性作用。\n\n\n\n　　夏瑜博士\n　　图片来源：DR\n　　在创始团队中，夏瑜负责公司总体战略规划、业务和科学发展方向。夏瑜说：“在企业发展的抉择时刻，需要的就是拍板的勇气，承担决策的压力和责任。确实考验领导者的深谋远虑和对企业发展的把控。”\n　　在“原创研发路线”战役取得丰硕成果之后，如今夏瑜带领着康方生物要面临的下一个挑战：产品商业化，从biotech走向为biopharma。\n　　在夏瑜看来，“有一些公司可能从创业之初就非常明确说不涉及生产，不涉及未来的商业化，就做自己擅长的事，这也是一种很好的商业模式。但有一些企业，比如康方生物，其实我是没有为未来设限的，只要条件允许，符合公司发展战略，我们就推进。\n　　第一个条件，比如说我是有足够的人才和能力去把生产和商业化都做起来，这就需要一个更大的企业发展目标来推动了。另外，作为创始人，我也要有这个理想，我觉得这非常重要。因为越做到生产和商业化这个阶段，某种意义上说不可控性更强，勇气是必须要有的。”\n　　明知山有虎，偏向虎山行。这就是夏瑜的执着与坚韧。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：刘万里 SF014","news_type":1,"symbols_score_info":{"09926":1}},"isVote":1,"tweetType":1,"viewCount":5375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171666399,"gmtCreate":1626742493411,"gmtModify":1703764212411,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583528354923579","idStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171666399","repostId":"1159080706","repostType":4,"repost":{"id":"1159080706","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626709038,"share":"https://ttm.financial/m/news/1159080706?lang=en_US&edition=fundamental","pubTime":"2021-07-19 23:37","market":"us","language":"zh","title":"[Unusual Movement] Wei Xiaoli recovers from today's losses and rebounds.","url":"https://stock-news.laohu8.com/highlight/detail?id=1159080706","media":"老虎资讯综合","summary":"7月19日，理想汽车、蔚来、小鹏汽车止跌回升，收复今日失地。\n小鹏汽车此前公布旗下搭载量产车规级激光雷达的小鹏P5的预售价格，并宣布开启预售，小鹏P5新车预售价格16-23万元，共推出6个不同续航配置","content":"<p>On July 19,<a href=\"https://laohu8.com/S/LI\">Li Auto</a>、<a href=\"https://laohu8.com/S/NIO\">Nio</a>、<a href=\"https://laohu8.com/S/XPEV\">XPeng Automotive</a>The price has stopped falling and rebounded, recovering the ground lost today.</p><p>XPeng previously announced the pre-sale price of its XPeng P5, which is equipped with mass-produced automotive-grade LiDAR, and announced the start of pre-sales. The new XPeng P5 will have a pre-sale price of 160,000 to 230,000 yuan, with a total of 6 versions with different range configurations to choose from, with a maximum range of 600 kilometers under NEDC conditions.</p><p>Meanwhile, XPeng Motor Company issued an announcement stating that it issued 12.0833 million shares on July 19, 2021, upon partial exercise of its over-allotment option, at an issue price of HK$165 per share.</p><p><img src=\"https://static.tigerbbs.com/f72a193fe4e67d7c18a4cbdff58c6864\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>[Unusual Movement] Wei Xiaoli recovers from today's losses and rebounds.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n[Unusual Movement] Wei Xiaoli recovers from today's losses and rebounds.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-07-19 23:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On July 19,<a href=\"https://laohu8.com/S/LI\">Li Auto</a>、<a href=\"https://laohu8.com/S/NIO\">Nio</a>、<a href=\"https://laohu8.com/S/XPEV\">XPeng Automotive</a>The price has stopped falling and rebounded, recovering the ground lost today.</p><p>XPeng previously announced the pre-sale price of its XPeng P5, which is equipped with mass-produced automotive-grade LiDAR, and announced the start of pre-sales. The new XPeng P5 will have a pre-sale price of 160,000 to 230,000 yuan, with a total of 6 versions with different range configurations to choose from, with a maximum range of 600 kilometers under NEDC conditions.</p><p>Meanwhile, XPeng Motor Company issued an announcement stating that it issued 12.0833 million shares on July 19, 2021, upon partial exercise of its over-allotment option, at an issue price of HK$165 per share.</p><p><img src=\"https://static.tigerbbs.com/f72a193fe4e67d7c18a4cbdff58c6864\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f36b37eb8e9efe8641c7be55a7da26d","relate_stocks":{"LI":"理想汽车","XPEV":"小鹏集团","09868":"小鹏集团-W","NIO":"蔚来"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159080706","content_text":"7月19日，理想汽车、蔚来、小鹏汽车止跌回升，收复今日失地。\n小鹏汽车此前公布旗下搭载量产车规级激光雷达的小鹏P5的预售价格，并宣布开启预售，小鹏P5新车预售价格16-23万元，共推出6个不同续航配置的版本可供选择，NEDC工况下最高续航达到600公里。\n同时，小鹏汽车发布公告，于2021年7月19日因部分行使超额配股权而发行1208.33万股，每股发行价为165港元。","news_type":1,"symbols_score_info":{"09868":0.9,"XPEV":0.9,"LI":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":5165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171612452,"gmtCreate":1626741721476,"gmtModify":1703764185350,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583528354923579","idStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171612452","repostId":"2152652777","repostType":4,"isVote":1,"tweetType":1,"viewCount":5072,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":884937555,"gmtCreate":1631845236277,"gmtModify":1676530650956,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/884937555","repostId":"1100031374","repostType":4,"repost":{"id":"1100031374","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631587259,"share":"https://ttm.financial/m/news/1100031374?lang=en_US&edition=fundamental","pubTime":"2021-09-14 10:40","market":"us","language":"zh","title":"Reminder: The Mid-Autumn Festival market closure schedule is here! Hong Kong stocks are closed on the 22nd.","url":"https://stock-news.laohu8.com/highlight/detail?id=1100031374","media":"老虎资讯综合","summary":"2021年中秋节假期即将来临！各主要市场休市安排如下：港股：\n\n\n9月22日（周三）休市。9月23日（周四）起照常开市。\n\n\nA股：\n\n\n9月20日（周一）至9月21日（周二）休市。9月22日（周三）起照常开市。\n\n\n美股、英股、澳股、新加坡股市照常交易。\n\n\n沪股通和深股通：\n\n\n9月17日（周五）至9月22日（周三）关闭。9月23日（周四）起照常开通。\n\n\n港股通：\n\n\n9月16日（周四）至9月22日（周三）关闭。9月23日（周四）起照常开通。","content":"<p>The 2021 Mid-Autumn Festival holiday is approaching! Market closure arrangements for each major market are as follows:<img src=\"https://static.tigerbbs.com/a514042f0cc485274181ed3db4bcf541\" tg-width=\"1103\" tg-height=\"746\" width=\"100%\" height=\"auto\"><b>Hong Kong stocks:</b></p><p>The market will be closed on Wednesday, September 22. The market will reopen as usual on Thursday, September 23.</p><p><b>A-shares:</b></p><p>The market will be closed from September 20 (Monday) to September 21 (Tuesday). The market will reopen as usual on Wednesday, September 22.</p><p><b>Trading in the US, UK, Australian, and Singapore stock markets will continue as usual.</b></p><p><b>Shanghai-Hong Kong Stock Connect and Shenzhen-Hong</b></p><p>Closed from Friday, September 17 to Wednesday, September 22. It will reopen as usual from Thursday, September 23.</p><p><b>Hong Kong Stock Connect:</b></p><p>Closed from September 16 (Thursday) to September 22 (Wednesday). It will reopen as usual from Thursday, September 23.</p><p><img src=\"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9\" tg-width=\"2048\" tg-height=\"1311\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reminder: The Mid-Autumn Festival market closure schedule is here! Hong Kong stocks are closed on the 22nd.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReminder: The Mid-Autumn Festival market closure schedule is here! Hong Kong stocks are closed on the 22nd.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-09-14 10:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>The 2021 Mid-Autumn Festival holiday is approaching! Market closure arrangements for each major market are as follows:<img src=\"https://static.tigerbbs.com/a514042f0cc485274181ed3db4bcf541\" tg-width=\"1103\" tg-height=\"746\" width=\"100%\" height=\"auto\"><b>Hong Kong stocks:</b></p><p>The market will be closed on Wednesday, September 22. The market will reopen as usual on Thursday, September 23.</p><p><b>A-shares:</b></p><p>The market will be closed from September 20 (Monday) to September 21 (Tuesday). The market will reopen as usual on Wednesday, September 22.</p><p><b>Trading in the US, UK, Australian, and Singapore stock markets will continue as usual.</b></p><p><b>Shanghai-Hong Kong Stock Connect and Shenzhen-Hong</b></p><p>Closed from Friday, September 17 to Wednesday, September 22. It will reopen as usual from Thursday, September 23.</p><p><b>Hong Kong Stock Connect:</b></p><p>Closed from September 16 (Thursday) to September 22 (Wednesday). It will reopen as usual from Thursday, September 23.</p><p><img src=\"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9\" tg-width=\"2048\" tg-height=\"1311\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/75ca986d45037f1a0b113e295b82f3f9","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100031374","content_text":"2021年中秋节假期即将来临！各主要市场休市安排如下：港股：\n9月22日（周三）休市。9月23日（周四）起照常开市。\nA股：\n9月20日（周一）至9月21日（周二）休市。9月22日（周三）起照常开市。\n美股、英股、澳股、新加坡股市照常交易。\n沪股通和深股通：\n9月17日（周五）至9月22日（周三）关闭。9月23日（周四）起照常开通。\n港股通：\n9月16日（周四）至9月22日（周三）关闭。9月23日（周四）起照常开通。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":6380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171612452,"gmtCreate":1626741721476,"gmtModify":1703764185350,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171612452","repostId":"2152652777","repostType":4,"isVote":1,"tweetType":1,"viewCount":5072,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884998842,"gmtCreate":1631844289386,"gmtModify":1676530650623,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884998842","repostId":"1115701930","repostType":4,"repost":{"id":"1115701930","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631842682,"share":"https://ttm.financial/m/news/1115701930?lang=en_US&edition=fundamental","pubTime":"2021-09-17 09:38","market":"other","language":"zh","title":"Hong Kong-listed mainland insurance stocks generally weakened, with Ping An Insurance falling more than 3%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1115701930","media":"老虎资讯综合","summary":"9月17日讯，港股内险股普遍走弱，中国平安跌3.1%，中国人民保险集团跌2.5%，中国太保、中国太平跌超2%。","content":"<p><img src=\"https://static.tigerbbs.com/62fb8bf9e6b0319be20ba231a920a5d8\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">September 17th - Mainland insurance stocks in Hong Kong generally weakened.<a href=\"https://laohu8.com/S/021318\">Ping An</a>It fell 3.1%.<a href=\"https://laohu8.com/S/01339\">People's Insurance Group of</a>It fell 2.5%.<a href=\"https://laohu8.com/S/601601\">China Pacific</a>、<a href=\"https://laohu8.com/S/00966\">China Taiping</a>It fell by more than 2%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong-listed mainland insurance stocks generally weakened, with Ping An Insurance falling more than 3%.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong-listed mainland insurance stocks generally weakened, with Ping An Insurance falling more than 3%.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-09-17 09:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><img src=\"https://static.tigerbbs.com/62fb8bf9e6b0319be20ba231a920a5d8\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">September 17th - Mainland insurance stocks in Hong Kong generally weakened.<a href=\"https://laohu8.com/S/021318\">Ping An</a>It fell 3.1%.<a href=\"https://laohu8.com/S/01339\">People's Insurance Group of</a>It fell 2.5%.<a href=\"https://laohu8.com/S/601601\">China Pacific</a>、<a href=\"https://laohu8.com/S/00966\">China Taiping</a>It fell by more than 2%.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","relate_stocks":{"601318":"中国平安","02318":"中国平安","03145":"华夏亚洲高息股","LU":"陆金所"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115701930","content_text":"9月17日讯，港股内险股普遍走弱，中国平安跌3.1%，中国人民保险集团跌2.5%，中国太保、中国太平跌超2%。","news_type":1,"symbols_score_info":{"601318":0.9,"03145":0.9,"02318":0.9,"LU":0.9}},"isVote":1,"tweetType":1,"viewCount":5671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819933613,"gmtCreate":1630026305032,"gmtModify":1676530202919,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819933613","repostId":"1123728452","repostType":2,"repost":{"id":"1123728452","kind":"news","weMediaInfo":{"introduction":"新三板第一媒体，由资深金融人和资深媒体人创办。","home_visible":1,"media_name":"读懂财经","id":"1060193092","head_image":"https://static.tigerbbs.com/0151ecd107de45069beb5d8f191d7326"},"pubTimestamp":1629982601,"share":"https://ttm.financial/m/news/1123728452?lang=en_US&edition=fundamental","pubTime":"2021-08-26 20:56","market":"hk","language":"zh","title":"JD Health, a \"pioneer\" in internet healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=1123728452","media":"读懂财经","summary":"「我们看见的不仅是一个海角，而是一个新的世界」。\n五百年前，历史学家巴若斯记录了他在抵达好望角时的感受：\n1488 年，巴若思乘坐葡萄牙航海家迪亚士率领的船队，从非洲西海岸南亚出发抵达这片海域时，他和","content":"<p>\"What we see is not just a cape, but a new world.\"</p><p>Five hundred years ago, the historian Barros recorded his feelings upon arriving at the Cape of Good Hope:</p><p>When Barros arrived in this area in 1488 aboard a fleet led by the Portuguese navigator Díaz from South Asia off the west coast of Africa, he, like everyone else, was speechless with excitement as he gazed at this long, narrow promontory.</p><p>For a considerable period prior to this, the Cape of Good Hope was known as the Cape of Storms, where huge waves caused by the collision of ocean currents continued year-round. Five hundred years later, when we created the Internet, it was like a navigator discovering a new route around the Cape of Good Hope, opening up opportunities for various industries.<a href=\"https://laohu8.com/S/600628\">New World</a>The door to internet healthcare is no exception.</p><p>The battlefield of Internet healthcare has always been in an environment of multi-party competition. In the past, the social value attribute centered on medical quality has always been the first principle of the medical and health industry. And now,<a href=\"https://laohu8.com/S/06618\">JD Health</a>By positioning itself in the supply chain, it undertook the implementation of more diverse medical service scenarios and eventually occupied a place in the industry.</p><p>From the perspective of financial data<a href=\"https://laohu8.com/S/JD\">JD.com</a>Health continues to experience high growth in the past. In the first half of this year, JD Health's total revenue was RMB 13.64 billion, a year-on-year increase of 55.4%. While business data grew rapidly, JD Health's gross profit margin declined by more than 1% year-on-year for the second consecutive year in the first half of the year. The reason is simple: in the first half of the year, the company provided users with a large number of free online consultations and continued to sell high-quality products at affordable prices to benefit users. Its business strategy can be described as quite \"down-to-earth\".</p><p>In the long run, the continuously improving quality of medical services and the \"down-to-earth\" business strategy are making JD Health's position in Internet healthcare more and more solid.</p><p><b>/01 /</b></p><p><b>The evolving \"ballast\" of the medical ecosystem</b></p><p>JD Health's \"retreat to advance\" strategy is rapidly expanding its medical ecosystem. According to the financial report, the expansion of JD Health's medical ecosystem is mainly reflected in three aspects: the continuous deepening of high-quality medical resources, the further consolidation of supply chain advantages, and the rapid growth of end users.</p><p>On the medical resource side, in order to better provide users with online medical and health services, JD Health has increased its expansion into high-quality medical care. As of June 30, 2021, JD Health Internet Hospital had 24 specialized centers, employing more than 130,000 doctors and medical experts, both in-house and in-house. Among them are well-known doctors such as Academician Han Demin, Professor Hu Dayi, Professor Gao Sihua, and Professor Lin Jiangtao.</p><p>With the addition of more and more national discipline leaders and top doctors, JD Health has further improved its internet medical and health service system. Thanks to this, JD Health received an average of over 160,000 daily online inquiries in the first half of the year, an increase of about 60% compared to the average daily online consultation volume for the whole of 2020.</p><p>As a long-standing strength of JD Health, its supply chain advantages were further strengthened in the first half of the year. On the one hand, JD Health's retail pharmacy business continues to expand its SKUs. As of June 30, 2021, JD Health's retail pharmacy business had more than 40 million products (SKUs), nearly doubling from the end of last year.</p><p>On the other hand, JD Health is also continuously strengthening its fulfillment capabilities. As of the first half of this year, \"JD Medicine Express\" has covered more than 300 cities across the country, providing users with medicine delivery services covering all time periods. Meanwhile, JD Health also helps offline micro and small enterprises reduce costs and increase efficiency through its digital and intelligent supply chain capabilities. Today, JD Health-Alliance Pharmacy has more than 500 cooperative stores, covering 17 provincial-level administrative regions across the country.</p><p>To some extent, JD Health's continuously abundant medical resources and constantly strengthening supply chain advantages are becoming the \"ballast\" of JD Health's entire medical ecosystem.</p><p>The continuous evolution of the \"ballast stone\" has also brought high user growth to JD Health. As of June 30, 2021, JD Health's annual active users reached 109 million in the past 12 months, a net increase of more than 18.8 million compared to the end of 2020.</p><p>At the same time, JD Health's family health management service product, JD Home Doctor, launched in 2020, also performed well. In the first half of 2021, JD Health's user activity rate reached 87%, and the average month-on-month growth rate of users since its launch has been 220%.</p><p><img src=\"https://static.tigerbbs.com/316175643f651a7c496a96da8e03e609\" tg-width=\"600\" tg-height=\"797\" referrerpolicy=\"no-referrer\"></p><p>With the full blossoming of the medical ecosystem, a solid foundation has been laid for the subsequent growth of JD Health.</p><p><b>/02 /</b></p><p><b>From \"medical +\" to \"medical ×\",</b></p><p><b>Full spillover of digital capabilities</b></p><p>While its B2C business continues To grow, JD Health's B2B services have also experienced a full-scale explosion. One obvious phenomenon is that JD Health is increasing its cooperation with all aspects of the healthcare industry chain and fully opening up its digital capabilities.</p><p><img src=\"https://static.tigerbbs.com/509b5bd8c78e99dff3f0872e54d64f1c\" tg-width=\"500\" tg-height=\"333\" referrerpolicy=\"no-referrer\"></p><p>From the current perspective, the implementation of JD Health's B2B services can be concentrated in three aspects: medical and health scenarios, doctor services, and regional medical informatization.</p><p>In terms of medical and health scenarios, JD Health is continuously exploring more diverse service scenarios. For example, the company uses the \"JD Home Doctor\" service as a standard module, along with...<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>Manufacturers of smart medical wearable devices such as speakers and smart bracelets have collaborated to combine \"JD Home Doctor\" products with smart hardware.</p><p>In addition, JD Health has also made breakthroughs in the health insurance scenario. In May, JD Health partnered with Fosun<a href=\"https://laohu8.com/S/UNH\">united health</a>JD.com<a href=\"https://laohu8.com/S/0M6S.UK\">Allianz Insurance</a>Several insurance companies, among others, have jointly launched a managed health insurance service called \"Home Medical Insurance\". With disease prevention and health improvement as its core objectives, this product combines health insurance with JD Health's medical services and health management capabilities, providing families with a one-stop lifelong medical and health services and health protection solution.</p><p>Diversified scenario penetration is of great significance to JD Health. In the short term, more scenarios can enrich JD Health's service and product categories. In the long run, the value of ecosystem companies often depends on the productivity of their ecosystem and their contribution ratio, and scenario extension is an important way to increase the proportion of ecosystem contribution.</p><p>On the doctor service side, JD Health builds a full-scenario operating ecosystem by providing doctors with services such as traffic construction, intelligent online tools, and exclusive rights, and continuously expands its ability to serve doctors.</p><p>For example, providing a safe practice environment for doctors. For both internet hospitals and doctors, clarity of responsibilities and personal risk prevention and control are the fundamental reasons why a doctor is willing to go online to an internet hospital. JD Health protects doctors' personal information security through a data security system, and then avoids online medical risks through process risk control and the purchase of medical liability insurance in online diagnosis and treatment. So, how should we understand the significance behind JD Health's empowerment of doctors?</p><p>In the field of healthcare in Internet plus, the improvement in productivity levels has largely relied on the internet doctor community. In other words, how to continuously enhance the value of Internet plus medical and health to doctors and better assist doctors in carrying out clinical research and diagnosis and treatment activities has naturally become the key to breaking through the current industry.</p><p>This is also the value of JD Health empowering doctors. Improving doctors' abilities through digital means can not only better attract excellent doctors into JD Health's ecosystem, but also bring a virtuous cycle to the entire ecosystem. This is also an ideal development \"path\" in the medical and health field in Internet plus.</p><p>In terms of industry empowerment, JD Health is promoting the sharing of medical and health information through its \"Healthy City\" strategy. Based on this, JD Health has also increased its cooperation with local governments and hospitals to create<a href=\"https://laohu8.com/S/300959\">Online and offline</a>An integrated healthcare service ecosystem. For example, in the first half of this year, JD Health partnered with the First Affiliated Hospital of Henan University of Traditional Chinese Medicine to build Henan's first TCM internet hospital, creating an \"innovative model\" for offline hospitals to improve their operational capabilities by building their own internet hospitals. Looking back over the past few years, JD Health has also reached strategic cooperation agreements with Yinchuan and Beihai to explore the regional implementation of the \"Internet plus Healthcare\" model.</p><p>At this point, JD Health's layout in the B-end market is gradually becoming clear. By penetrating more diverse scenarios, we can deeply explore the diverse needs of users; Technology empowers doctors, connecting high-quality medical resources while improving industry efficiency; Through cooperation with cities across the country, we will promote the overall implementation of medical informatization.</p><p>Looking at a longer timeframe, the multiplier effect brought about by ecosystem openness will gradually be reflected in JD Health.</p><p><b>/03 /</b></p><p><b>JD.com's \"genes\" behind the industry</b></p><p>JD Health is making unprecedented inroads into the medical industry to serve the real economy. This is inseparable from JD.com's long-standing \"physical\" DNA.</p><p>Similar to JD.com's digital transformation of the e-commerce industry, JD Health is transforming the medical and health industry in the same way. This is reflected in two aspects:</p><p>From a starting point perspective, whether it's JD.com or JD Health, digital technology is the starting point for empowering the industry. Looking at the entire internet industry, JD.com has consistently been one of the technology companies with the largest technological investment in China. Over the past four years, JD.com has invested nearly 60 billion yuan in R&D.</p><p>JD.com's technological DNA is also deeply imprinted on JD Health. For a considerable period of time, JD Health has been continuously investing in technological research and development to improve doctor efficiency and optimize user experience.</p><p>In the first half of 2021, JD Health continued to increase its R&D investment, focusing on improving user experience and creating digital and intelligent tools for doctors. Taking JD Home Doctor as an example, through cooperation with smart hardware, JD Home Doctor has \"implanted\" online consultations that originally needed to be completed through a mobile APP into a smart speaker that can summon services by voice, and launched the \"JD Home Doctor Filial Piety Edition\" which is more suitable for the elderly, breaking through the traditional interaction method of online consultation.</p><p>From the underlying logic, both sides are continuously creating social value in different ways. JD.com needs no further explanation. Through solid supply chain management, JD.com's image of \"speed, efficiency, and cost-effectiveness\" in the retail sector has become deeply ingrained in people's minds.</p><p>For JD Health, inclusive healthcare is its focus in creating social value. For example, in response to sudden disasters, JD Health has comprehensively upgraded its emergency response mechanism this year to ensure timely support for residents' health protection.</p><p>This mechanism also played an important role in the recent severe rainstorm disaster in Henan. During the severe rainstorm in Henan, JD Health immediately launched flood prevention and assistance operations, including launching a 24-hour free online consultation zone. At the same time, the company urgently established and dispatched an offline medical rescue team to conduct on-site diagnosis and treatment.</p><p>From a broader perspective, JD Health continuously empowers the medical industry and improves the overall efficiency of the industry through digital means, which is also fulfilling its social responsibility.</p><p>Of course, compared with the retail industry, the process of digitalization transforming the healthcare industry may be longer. However, this also means that once the transformation is completed, JD Health's commercial moat will be even more solid. Considering that healthcare itself is a huge market, as JD Health's healthcare ecosystem takes shape, it is not impossible to \"create another JD.com\".</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health, a \"pioneer\" in internet healthcare</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health, a \"pioneer\" in internet healthcare\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060193092\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/0151ecd107de45069beb5d8f191d7326);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">读懂财经 </p>\n<p class=\"h-time smaller\">2021-08-26 20:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>\"What we see is not just a cape, but a new world.\"</p><p>Five hundred years ago, the historian Barros recorded his feelings upon arriving at the Cape of Good Hope:</p><p>When Barros arrived in this area in 1488 aboard a fleet led by the Portuguese navigator Díaz from South Asia off the west coast of Africa, he, like everyone else, was speechless with excitement as he gazed at this long, narrow promontory.</p><p>For a considerable period prior to this, the Cape of Good Hope was known as the Cape of Storms, where huge waves caused by the collision of ocean currents continued year-round. Five hundred years later, when we created the Internet, it was like a navigator discovering a new route around the Cape of Good Hope, opening up opportunities for various industries.<a href=\"https://laohu8.com/S/600628\">New World</a>The door to internet healthcare is no exception.</p><p>The battlefield of Internet healthcare has always been in an environment of multi-party competition. In the past, the social value attribute centered on medical quality has always been the first principle of the medical and health industry. And now,<a href=\"https://laohu8.com/S/06618\">JD Health</a>By positioning itself in the supply chain, it undertook the implementation of more diverse medical service scenarios and eventually occupied a place in the industry.</p><p>From the perspective of financial data<a href=\"https://laohu8.com/S/JD\">JD.com</a>Health continues to experience high growth in the past. In the first half of this year, JD Health's total revenue was RMB 13.64 billion, a year-on-year increase of 55.4%. While business data grew rapidly, JD Health's gross profit margin declined by more than 1% year-on-year for the second consecutive year in the first half of the year. The reason is simple: in the first half of the year, the company provided users with a large number of free online consultations and continued to sell high-quality products at affordable prices to benefit users. Its business strategy can be described as quite \"down-to-earth\".</p><p>In the long run, the continuously improving quality of medical services and the \"down-to-earth\" business strategy are making JD Health's position in Internet healthcare more and more solid.</p><p><b>/01 /</b></p><p><b>The evolving \"ballast\" of the medical ecosystem</b></p><p>JD Health's \"retreat to advance\" strategy is rapidly expanding its medical ecosystem. According to the financial report, the expansion of JD Health's medical ecosystem is mainly reflected in three aspects: the continuous deepening of high-quality medical resources, the further consolidation of supply chain advantages, and the rapid growth of end users.</p><p>On the medical resource side, in order to better provide users with online medical and health services, JD Health has increased its expansion into high-quality medical care. As of June 30, 2021, JD Health Internet Hospital had 24 specialized centers, employing more than 130,000 doctors and medical experts, both in-house and in-house. Among them are well-known doctors such as Academician Han Demin, Professor Hu Dayi, Professor Gao Sihua, and Professor Lin Jiangtao.</p><p>With the addition of more and more national discipline leaders and top doctors, JD Health has further improved its internet medical and health service system. Thanks to this, JD Health received an average of over 160,000 daily online inquiries in the first half of the year, an increase of about 60% compared to the average daily online consultation volume for the whole of 2020.</p><p>As a long-standing strength of JD Health, its supply chain advantages were further strengthened in the first half of the year. On the one hand, JD Health's retail pharmacy business continues to expand its SKUs. As of June 30, 2021, JD Health's retail pharmacy business had more than 40 million products (SKUs), nearly doubling from the end of last year.</p><p>On the other hand, JD Health is also continuously strengthening its fulfillment capabilities. As of the first half of this year, \"JD Medicine Express\" has covered more than 300 cities across the country, providing users with medicine delivery services covering all time periods. Meanwhile, JD Health also helps offline micro and small enterprises reduce costs and increase efficiency through its digital and intelligent supply chain capabilities. Today, JD Health-Alliance Pharmacy has more than 500 cooperative stores, covering 17 provincial-level administrative regions across the country.</p><p>To some extent, JD Health's continuously abundant medical resources and constantly strengthening supply chain advantages are becoming the \"ballast\" of JD Health's entire medical ecosystem.</p><p>The continuous evolution of the \"ballast stone\" has also brought high user growth to JD Health. As of June 30, 2021, JD Health's annual active users reached 109 million in the past 12 months, a net increase of more than 18.8 million compared to the end of 2020.</p><p>At the same time, JD Health's family health management service product, JD Home Doctor, launched in 2020, also performed well. In the first half of 2021, JD Health's user activity rate reached 87%, and the average month-on-month growth rate of users since its launch has been 220%.</p><p><img src=\"https://static.tigerbbs.com/316175643f651a7c496a96da8e03e609\" tg-width=\"600\" tg-height=\"797\" referrerpolicy=\"no-referrer\"></p><p>With the full blossoming of the medical ecosystem, a solid foundation has been laid for the subsequent growth of JD Health.</p><p><b>/02 /</b></p><p><b>From \"medical +\" to \"medical ×\",</b></p><p><b>Full spillover of digital capabilities</b></p><p>While its B2C business continues To grow, JD Health's B2B services have also experienced a full-scale explosion. One obvious phenomenon is that JD Health is increasing its cooperation with all aspects of the healthcare industry chain and fully opening up its digital capabilities.</p><p><img src=\"https://static.tigerbbs.com/509b5bd8c78e99dff3f0872e54d64f1c\" tg-width=\"500\" tg-height=\"333\" referrerpolicy=\"no-referrer\"></p><p>From the current perspective, the implementation of JD Health's B2B services can be concentrated in three aspects: medical and health scenarios, doctor services, and regional medical informatization.</p><p>In terms of medical and health scenarios, JD Health is continuously exploring more diverse service scenarios. For example, the company uses the \"JD Home Doctor\" service as a standard module, along with...<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>Manufacturers of smart medical wearable devices such as speakers and smart bracelets have collaborated to combine \"JD Home Doctor\" products with smart hardware.</p><p>In addition, JD Health has also made breakthroughs in the health insurance scenario. In May, JD Health partnered with Fosun<a href=\"https://laohu8.com/S/UNH\">united health</a>JD.com<a href=\"https://laohu8.com/S/0M6S.UK\">Allianz Insurance</a>Several insurance companies, among others, have jointly launched a managed health insurance service called \"Home Medical Insurance\". With disease prevention and health improvement as its core objectives, this product combines health insurance with JD Health's medical services and health management capabilities, providing families with a one-stop lifelong medical and health services and health protection solution.</p><p>Diversified scenario penetration is of great significance to JD Health. In the short term, more scenarios can enrich JD Health's service and product categories. In the long run, the value of ecosystem companies often depends on the productivity of their ecosystem and their contribution ratio, and scenario extension is an important way to increase the proportion of ecosystem contribution.</p><p>On the doctor service side, JD Health builds a full-scenario operating ecosystem by providing doctors with services such as traffic construction, intelligent online tools, and exclusive rights, and continuously expands its ability to serve doctors.</p><p>For example, providing a safe practice environment for doctors. For both internet hospitals and doctors, clarity of responsibilities and personal risk prevention and control are the fundamental reasons why a doctor is willing to go online to an internet hospital. JD Health protects doctors' personal information security through a data security system, and then avoids online medical risks through process risk control and the purchase of medical liability insurance in online diagnosis and treatment. So, how should we understand the significance behind JD Health's empowerment of doctors?</p><p>In the field of healthcare in Internet plus, the improvement in productivity levels has largely relied on the internet doctor community. In other words, how to continuously enhance the value of Internet plus medical and health to doctors and better assist doctors in carrying out clinical research and diagnosis and treatment activities has naturally become the key to breaking through the current industry.</p><p>This is also the value of JD Health empowering doctors. Improving doctors' abilities through digital means can not only better attract excellent doctors into JD Health's ecosystem, but also bring a virtuous cycle to the entire ecosystem. This is also an ideal development \"path\" in the medical and health field in Internet plus.</p><p>In terms of industry empowerment, JD Health is promoting the sharing of medical and health information through its \"Healthy City\" strategy. Based on this, JD Health has also increased its cooperation with local governments and hospitals to create<a href=\"https://laohu8.com/S/300959\">Online and offline</a>An integrated healthcare service ecosystem. For example, in the first half of this year, JD Health partnered with the First Affiliated Hospital of Henan University of Traditional Chinese Medicine to build Henan's first TCM internet hospital, creating an \"innovative model\" for offline hospitals to improve their operational capabilities by building their own internet hospitals. Looking back over the past few years, JD Health has also reached strategic cooperation agreements with Yinchuan and Beihai to explore the regional implementation of the \"Internet plus Healthcare\" model.</p><p>At this point, JD Health's layout in the B-end market is gradually becoming clear. By penetrating more diverse scenarios, we can deeply explore the diverse needs of users; Technology empowers doctors, connecting high-quality medical resources while improving industry efficiency; Through cooperation with cities across the country, we will promote the overall implementation of medical informatization.</p><p>Looking at a longer timeframe, the multiplier effect brought about by ecosystem openness will gradually be reflected in JD Health.</p><p><b>/03 /</b></p><p><b>JD.com's \"genes\" behind the industry</b></p><p>JD Health is making unprecedented inroads into the medical industry to serve the real economy. This is inseparable from JD.com's long-standing \"physical\" DNA.</p><p>Similar to JD.com's digital transformation of the e-commerce industry, JD Health is transforming the medical and health industry in the same way. This is reflected in two aspects:</p><p>From a starting point perspective, whether it's JD.com or JD Health, digital technology is the starting point for empowering the industry. Looking at the entire internet industry, JD.com has consistently been one of the technology companies with the largest technological investment in China. Over the past four years, JD.com has invested nearly 60 billion yuan in R&D.</p><p>JD.com's technological DNA is also deeply imprinted on JD Health. For a considerable period of time, JD Health has been continuously investing in technological research and development to improve doctor efficiency and optimize user experience.</p><p>In the first half of 2021, JD Health continued to increase its R&D investment, focusing on improving user experience and creating digital and intelligent tools for doctors. Taking JD Home Doctor as an example, through cooperation with smart hardware, JD Home Doctor has \"implanted\" online consultations that originally needed to be completed through a mobile APP into a smart speaker that can summon services by voice, and launched the \"JD Home Doctor Filial Piety Edition\" which is more suitable for the elderly, breaking through the traditional interaction method of online consultation.</p><p>From the underlying logic, both sides are continuously creating social value in different ways. JD.com needs no further explanation. Through solid supply chain management, JD.com's image of \"speed, efficiency, and cost-effectiveness\" in the retail sector has become deeply ingrained in people's minds.</p><p>For JD Health, inclusive healthcare is its focus in creating social value. For example, in response to sudden disasters, JD Health has comprehensively upgraded its emergency response mechanism this year to ensure timely support for residents' health protection.</p><p>This mechanism also played an important role in the recent severe rainstorm disaster in Henan. During the severe rainstorm in Henan, JD Health immediately launched flood prevention and assistance operations, including launching a 24-hour free online consultation zone. At the same time, the company urgently established and dispatched an offline medical rescue team to conduct on-site diagnosis and treatment.</p><p>From a broader perspective, JD Health continuously empowers the medical industry and improves the overall efficiency of the industry through digital means, which is also fulfilling its social responsibility.</p><p>Of course, compared with the retail industry, the process of digitalization transforming the healthcare industry may be longer. However, this also means that once the transformation is completed, JD Health's commercial moat will be even more solid. Considering that healthcare itself is a huge market, as JD Health's healthcare ecosystem takes shape, it is not impossible to \"create another JD.com\".</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3cfc5f3c5c9987e1de0c5ad74e29feb3","relate_stocks":{"06618":"京东健康"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123728452","content_text":"「我们看见的不仅是一个海角，而是一个新的世界」。\n五百年前，历史学家巴若斯记录了他在抵达好望角时的感受：\n1488 年，巴若思乘坐葡萄牙航海家迪亚士率领的船队，从非洲西海岸南亚出发抵达这片海域时，他和所有人一样，当凝望着这狭长的岬角时，激动得说不出话来。\n在此前相当长的时间里，好望角都因海流相撞引起的滔天巨浪终年不息，被称为风暴角。五百年后，当我们创造出互联网，就像航海家绕过好望角发现新航路一般，给各个行业都打开了一个新世界的大门，互联网医疗也不例外。\n在互联网医疗的战场，一直处于多方竞争的环境中。从过去看，以医疗质量为核心的社会价值属性始终是医疗健康产业的第一性原理。而如今，京东健康以供应链卡位切入，承接更多元的医疗服务场景落地，最终在行业占据了一席之地。\n从财务数据看，京东健康仍然在延续过去的高增长。今年上半年，京东健康总收入为人民币136.4亿元，同比增长55.4%。在业务数据高速增长的同时，京东健康上半年毛利率连续两年同比下降超过1%。原因很简单，上半年公司为用户免费提供大量在线咨询、以及将优质商品持续平价销售以让利用户，经营策略可谓相当“接地气”。\n拉长周期看，不断提高的医疗服务质量，以及“接地气”的经营策略，正在让京东健康在互联网医疗的地位愈发稳固。\n/ 01 /\n仍在进化的医疗生态「压舱石」\n京东健康“以退为进”的策略，正在让其医疗生态迅速扩大。从财报看，京东健康医疗生态的扩张主要体现在三个层面：优质医疗资源持续做深、供应链优势进一步夯实，以及终端用户高速增长。\n在医疗资源端，为了更好地为用户提供在线医疗健康服务，京东健康加大了对优质医疗的开拓。截至2021年6月30日，京东健康互联网医院开设的专科中心已增至24个，吸纳自有和外部合作医生及医疗专家超过13万名。其中，不乏韩德民院士、胡大一教授、高思华教授、林江涛教授等知名医生。\n随着越来越多的全国学科带头人级别的专家和顶级名医的加入，京东健康进一步完善了互联网医疗健康服务体系。得益于此，京东健康在上半年日均在线咨询量超过16万，较2020年全年日均在线问诊量提升60%左右。\n而作为京东健康一直以来的优势项目，其供应链优势也在上半年得到进一步夯实。一方面，京东健康零售药房业务的SKU持续扩充。截至2021年6月30日，京东健康零售药房业务已有超过4000万个商品（SKU），较去年年底接近翻倍。\n另一方面，京东健康也在不断强化自身的履约能力。截至今年上半年，“京东药急送”已覆盖全国超过300个城市，为用户提供覆盖全时段的送药服务。同时，京东健康还通过数智化供应链能力助力线下小微企业降本增效。如今，京东健康-联盟大药房累计合作门店已超过500家，覆盖全国17个省级行政区。\n某种程度上说，持续丰富的医疗资源和不断夯实的供应链优势，正在成为京东健康整个医疗生态的“压舱石”。\n“压舱石”的持续进化，也为京东健康带来了用户端的高增长。截至2021年6月30日，京东健康过去12个月的年度活跃用户数量达到1.09亿，较2020年底的用户数净增加超过1880万。\n与此同时，京东健康2020年推出的家庭健康管理服务产品——京东家医，同样表现不俗。2021年上半年，京东健康的用户活跃占比达87%，上线至今用户数月平均环比增速220%。\n\n随着医疗生态的全面开花，也为京东健康后续的增长打下坚实基础。\n/ 02 /\n从“医疗+”到“医疗×”，\n数字化能力全面外溢\n在To C业务持续增长的同时，京东健康的To B服务也迎来了全面爆发。一个明显的现象是，京东健康正在加大与医疗健康产业链各个环节的合作，全面开放自己的数字化能力。\n\n从目前看，京东健康To B服务的落地，可以集中体现在医疗健康场景、医生服务和区域医疗信息化三个方面。\n在医疗健康场景方面，京东健康正在持续开拓更多元的服务场景。比如，公司将“京东家医”服务作为标准模块，与智能音箱、智能手环等智能医用可穿戴设备厂商开展合作，实现“京东家医”产品与智能硬件的结合。\n此外，在健康险场景上京东健康也有所突破。5月，京东健康联合复星联合健康、京东安联保险等多家保险公司，共同推出了管理型健康险服务——“家医保”。该产品以预防疾病、改善健康为核心目的，将健康险与京东健康的医疗服务、健康管理能力相结合，为家庭提供了一站式终身医疗健康服务和健康保障解决方案。\n多元化场景渗透，对京东健康的意义巨大。短期看，更多场景能够丰富京东健康的服务和产品类别。而拉长周期看，生态型公司的价值往往都取决于其所在生态的生产率，以及它们的贡献占比，而场景延伸正是提升生态贡献占比的重要途径。\n在医生服务端，京东健康通过为医生提供流量建设、智慧化线上工具、专属权益等服务，构建全场景的运营生态，不断拓展着为医生服务的能力。\n比如，为医生提供安全的执业环境。无论是对于互联网医院还是医生而言，职责的清晰以及个人风险防控是一个医生愿意上线互联网医院的根本所在。京东健康通过数据安全体系保护医生个人的信息安全，再通过线上诊疗中的流程风控、医责险的购置等规避在线诊疗风险。那么，在京东健康对医生赋能背后，我们应该如何理解其意义？\n在互联网+医疗健康领域，生产力水平的提升，很大程度上是依靠互联网医生群体完成的。换句话说，如何不断提升互联网+医疗健康之于医生的价值，更好地辅助医生开展临床科研和诊疗活动，自然成为当前行业破局的关键。\n这也是京东健康赋能医生的价值所在，通过数字化手段提升医生能力，不仅能更好吸引优秀医生进入京东健康的生态系统中，更能为整个生态系统带来良性循环。这也不失为互联网+医疗健康领域里一种理想的发展“路径”。\n在产业赋能看，京东健康正在以“健康城市”战略推进医疗健康信息互通共享。基于此，京东健康也加大了与地方政府、医院合作，打造线上线下一体化医疗健康服务生态。比如，今年上半年，京东健康与河南中医药大学第一附属医院合作搭建了河南首家中医互联网医院，打造线下医院自建互联网医院提升运营能力的“创新样本”。回顾过去几年，京东健康也与银川、北海多地达成战略合作，探索“互联网+医疗健康”模式在区域化的落地。\n至此，京东健康在B端的布局逐渐清晰。通过更多元的场景渗透，深度挖掘用户的多样化需求；科技赋能医生，在连接优质医疗资源的同时，提升产业效率；通过与各地城市的合作，推动医疗信息化的整体落地。\n拉长周期看，生态开放带来的乘数效应，也将逐渐在京东健康上得到体现。\n/ 03 /\n深入产业背后的京东“基因”\n京东健康正在史无前例地深入医疗产业之中，服务实体经济。这背后离不开京东这家公司一直以来的“实体”基因。\n与京东集团通过数字化改造电商行业类似，京东健康正在以同样的路径改造着医疗健康产业。体现在两个层面：\n从起点看，无论是京东，还是京东健康，数字化技术都是其赋能行业的起点。放眼整个互联网行业，京东一直都是国内技术投入最大的科技企业之一。过去4年，京东体系四年累计研发费用投入近600亿元。\n京东的技术基因，也深深烙在了京东健康这家公司上。在过去相当长时间里，京东健康都通过不断的技术研发投入，提升医生效率、优化用户体验。\n2021上半年，京东健康持续加大研发投入，并重点用于用户体验提升和医生数智化工具的打造。以京东家医为例，京东家医通过与智能硬件的合作，将原本需要通过手机APP完成的在线咨询，“植入”了可语音唤起服务的智能音箱中，推出更适合老年人使用的“京东家医孝心版”，突破了传统在线咨询的交互方式。\n从底层逻辑看，双方都在以不同的方式，持续创造着社会价值。京东自然不必多说。通过扎实的供应链管理，京东在零售领域“多快好省”的形象已经深入人心。\n对京东健康来说，普惠医疗就是其创造社会价值的着力点。比如，针对突发灾害事件，京东健康今年全面升级应急回应机制，以确保第一时间支持居民健康保障。\n这样的机制，也在本次河南特大暴雨灾害发挥了重要作用。在河南特大暴雨灾害中，京东健康第一时间展开防汛援助行动，包括上线24小时免费在线咨询专区。与同此时，公司紧急组建并派出线下医疗救援队，开展现场诊疗。\n站在更大维度上去看，京东健康通过数字化手段，持续赋能医疗产业，提升行业整体效率，又何尝不是在践行社会责任呢？\n固然，与零售行业相比，数字化对医疗健康行业的改造进程可能更为漫长。但这也意味着，一旦改造完成，京东健康的商业护城河也更为牢固。考虑到医疗健康本身是一个巨大市场，随着京东健康的医疗健康生态日益成型，“再造一个京东”也未尝没有可能。","news_type":1,"symbols_score_info":{"06618":0.9}},"isVote":1,"tweetType":1,"viewCount":4984,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801885858,"gmtCreate":1627508922774,"gmtModify":1703491180130,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801885858","repostId":"2154992231","repostType":2,"repost":{"id":"2154992231","kind":"news","pubTimestamp":1627378800,"share":"https://ttm.financial/m/news/2154992231?lang=en_US&edition=fundamental","pubTime":"2021-07-27 17:40","market":"hk","language":"zh","title":"Forbes China Interview with Xia Yu, Chairman of Akeso Biologics: Leaning Towards a Tiger's Den","url":"https://stock-news.laohu8.com/highlight/detail?id=2154992231","media":"财经自媒体","summary":"　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”　　今年4月，康方生物公布了上市后的首份年度成绩单。","content":"<p><html><body><div><p cms-style=\"font-L\">Source: Forbes</p><p><p cms-style=\"font-L\">In the field of pharmaceutical innovation,<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>、<a href=\"https://laohu8.com/S/JNJ\">Johnson and Johnson</a>、<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>、<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>With numerous international giants emerging, it may not be feasible to hone one's skills in ten years.</p><p><p cms-style=\"font-L\">Xia Yu, founder and chairman of Akeso Biopharma, told Forbes China:<span><a href=\"https://laohu8.com/S/600056\">Chinese medicine</a></span><span></span>The true rise of innovation must rely on its own strength, cultivate an innovation atmosphere, build an innovation system, and achieve breakthroughs in innovation achievements. From the perspective of the business model of global industry development, there is no problem with the model of buying, buying, buying, but leading giants in the pharmaceutical industry such as Pfizer, Johnson & Johnson, AstraZeneca, and Novo Nordisk, pharmaceutical companies with a place in the world, should China appear? \"</p><p><p cms-style=\"font-L\">\"China should emerge,\" Xia Yu said firmly, adding that these companies' own R&D and innovation capabilities are key to becoming world-class leaders.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/324/w550h574/20210727/9053-eb59dd1acbf005315f9f014538a392da.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Xia Yu, founder and chairman of Akeso Biotech Co., Ltd.</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">However, where should Chinese pharmaceutical companies that can compete with or even surpass giants place their hopes?</p><p><p cms-style=\"font-L\">In April of this year, Akeso Biotech released its first annual performance report since its listing. The announcement shows that as of the end of 2020, Akeso Biotech's other income and gains exceeded 100 million yuan; R&D investment reached 764.5 million yuan.</p><p><p cms-style=\"font-L\">After ten years of entrepreneurship, Akeso Biologics has finally pioneered a pioneering track in the research and development of original Chinese antibody drugs: among more than 20 drugs under development, 6 are world-first or leading bispecific antibodies, the research and development progress of many cutting-edge target drug candidates is world-leading, more than 20 clinical research projects are in Phase II clinical trials and beyond, and the core world-first bispecific antibodies are about to be launched... A Chinese biotechnology company that has truly gone global through self-development has quietly risen.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/80/w550h330/20210727/0264-3242e677075ee7bd62b8859c7068fc7c.jpg\"/><span></span></div></div><p cms-style=\"font-L\">World's first bispecific antibody cadonilimab</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The buy-buy-buy model can't buy China's Pfizer or China's Johnson & Johnson.</font></p><p><p cms-style=\"font-L\">More than a decade ago, Xia Yu, who had built a comfortable and superior life in a foreign land, returned to China and had the idea of starting a business amidst the bustling crowds of Beijing. As a Chinese person, the first question that comes to Xia Yu's mind is whether China needs original new drugs. Are Chinese people only allowed to use outdated foreign medicines from ten years ago for decades?</p><p><p cms-style=\"font-L\">“Actually, if I were doing the same thing (pharmaceutical research and development) in the United States, I would very likely stop after a certain stage of research and development,” Xia Yu further said. “Because I myself know very well that the investment in production, commercialization, and even clinical trials after research and development is just too huge. But today, with the development of the domestic pharmaceutical industry, whether from the perspective of capital market development or industrial policy support, China actually has the possibility of conquering the global industry high ground.”</p><p><p cms-style=\"font-L\">Of course, a natural shortcoming for Chinese pharmaceutical companies in participating in global competition is their late start and relatively backward overall development level of the industry. \"But the gap does not mean that we cannot achieve world leadership in certain fields, directions, or stages.\"</p><p><p cms-style=\"font-L\">Xia Yu is well aware that there are two paths to choose from when entering the pharmaceutical industry. One path is original research and development, which involves using the company's own internal research and development capabilities to obtain competitive innovative drugs. Another approach is to improve the company's R&D pipeline through external introductions.</p><p><p cms-style=\"font-L\">Ten years ago, the research and development of new drugs in China's pharmaceutical industry was \"poor and white\". Xia Yu still chose the path of originality.</p><p><p cms-style=\"font-L\">Even in recent years, the return of a number of overseas returnee entrepreneurs has actually driven the return of individual advanced technologies. However, Xia Yu has been thinking and practicing how to drive the overall pharmaceutical industry to cultivate and develop in China, and how to establish a truly advanced R&D system in China. Without being in a hurry, or even sacrificing the opportunity to produce advanced products, Xia Yu led Akeso Biotech to invest huge energy in creating an integrated R&D system internally from the very beginning of its establishment.</p><p><p cms-style=\"font-L\">Only under such an innovative R&D system, with this willingness and ideal to grow, from the source of R&D to industrialization, will China's Pfizer and China's Johnson & Johnson emerge in the future.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/40/w550h290/20210727/55da-1b43fa5d55b5db075d491294cb78bfd6.png\"/><span></span></div></div><p cms-style=\"font-L\">Exterior view of Akeso Biotech's Guangzhou base</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">Since its establishment in 2012, Akeso Biologics has focused on developing the world's most cutting-edge tumor immunotherapy antibodies, starting with the most advanced original scientific research and innovation, all the way to the layout of production, commercialization and clinical trials. Currently, Akeso has developed more than 20 innovative drug candidates, of which 13 innovative antibody drugs are in the clinical research stage.</p><p><p cms-style=\"font-L\">\"Actually, not developing original new drugs is an understandable business model. The only problem I think is that this matter has become a red ocean, and anything that enters a red ocean will be terrifying.\" In China, an industrial reality facing drug regulation is that even in 2016, the total R&D investment of pharmaceutical companies nationwide was still less than that of the world's largest pharmaceutical company.</p><p><p cms-style=\"font-L\">\"On the one hand, we need to create fertile ground for industrial development; on the other hand, we must establish a competitive mechanism based on survival of the fittest. The current pharmaceutical giants in the United States are also the result of survival of the fittest after industrial development and market competition. A similar scenario is expected to emerge in China in the future,\" Xia Yu said.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The stark contrast between ice and fire: the double-edged sword of capital.</font></p><p><p cms-style=\"font-L\">Even in the past two years, with the reform of the Hong Kong Stock Exchange's new share listing system and the introduction of the registration system of the Science and Technology Innovation Board, new financing opportunities and more diverse choices have been provided to pharmaceutical companies with different market orientations, different investor compositions, and different entry and exit mechanisms. What remains unchanged is that the business model for starting a business must be able to withstand the test of capital preservation and appreciation capabilities.</p><p><p cms-style=\"font-L\">Xia Yu recalled that in the early stages of starting a business, if we really couldn't get the financial support of the capital market, we might have survived in other ways, but it is certain that it would have been far from possible to achieve the rapid development we have now. A significant role of capital is to help accelerate the development of enterprises, allowing them to focus more on building robust innovative competitiveness in a competitive environment.</p><p><p cms-style=\"font-L\">　　<a href=\"https://laohu8.com/S/V03.SI\">Startup company</a>The business model chosen at each stage of development will be reflected differently at different stages of development.</p><p><p cms-style=\"font-L\">At the beginning of the business in 2012, drug innovation companies were not as sought after in the capital market as they are now. In order to survive and continue to develop, at the end of 2015, Xia Yu decided to license an innovative product from Akeso Biotech to a giant.<a href=\"https://laohu8.com/S/MRK\">Merck</a>。 \"I think from a business model perspective, at that moment it was definitely a decision that was beneficial to the company's long-term development and supported our long-term development.\" On the other hand, this is the first time that an innovative antibody drug independently developed by a Chinese domestic company has been licensed to a TOP5 international pharmaceutical giant. It has also become one of the landmark events for China's innovative drug industry to truly go international and gain international recognition, and it has also allowed Akeso Biotech to step onto the world stage of drug innovation for the first time.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/117/w550h367/20210727/b886-3bb61d586babf8c3cb5f2b87668503b0.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Production workshop</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">\"Actually, I understand the capital market very well. In the early stages of our business, we spent a lot of time developing the platform, which is why we have achieved many results on the platform now. At Kangfang, while efficiently advancing the clinical development of our existing pipeline, we will focus more on cutting-edge target drugs in product development. This is because we already have a good product foundation and development experience, and have also gained the recognition of investors.\" But if I took investors' money to do 10 years of innovative research and development without any products at all, which investor would agree?</p><p><p cms-style=\"font-L\">If the birth of a new drug is a relay race for various companies in the industry chain, Xia Yu's determination is a marathon.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">From studying abroad alone to returning to China to start a business with a market value of 50 billion yuan</font></p><p><p cms-style=\"font-L\">A noteworthy phenomenon is that nearly 20% of the founders of emerging innovative companies in the pharmaceutical industry are women. Having accumulated extensive experience in biopharmaceutical research and development, Xia Yu, as an antibody drug research and development expert, decided to return to China to start a business and found Akeso Biotech with three other returnees. Xia Yu, as chairman, is the only woman in the management team.</p><p><p cms-style=\"font-L\">Xia Yu said, \"Women are more tolerant, more resilient, and more dedicated and persistent in doing something.\"</p><p><p cms-style=\"font-L\">\"But all perfection is relative, and there is no perfect persona in entrepreneurship.\"</p><p><p cms-style=\"font-L\">Just as Xia Yu initially decided to return to China to start a business, even with the support of her daughter's family, she still had to face the incomprehension of those around her. As a mother, shouldn't she be there for her daughter wholeheartedly during this crucial stage of her growth? As a woman, why would she still pursue a so-called career when she is living a comfortable life in middle age?</p><p><p cms-style=\"font-L\">With an incomprehensible sting, Xia Yu and her daughter transformed and grew together. Now, her daughter says that her mother is the person she admires most.</p><p><p cms-style=\"font-L\">At this point, more than ten years had passed since Xia Yu single-handedly founded Akeso Biotech.</p><p><p cms-style=\"font-L\">Following Akeso Biologics' official listing on the Hong Kong Stock Exchange in 2020, its total market capitalization has now reached HK$55 billion.</p><p><p cms-style=\"font-L\">Looking back on her youth, Xia Yu, who was a top student, said, \"I went abroad right after graduating from university. At that time, I relied entirely on myself to get a scholarship and ran abroad with only a few dollars in my pocket. When I went abroad, I found that it was a world of difference from China. I was very nervous at the time and didn't know what would happen next.\"</p><p><p cms-style=\"font-L\">Over the next 20 years, Xia Yu worked at Sino-American Crown Biotechnology,<a href=\"https://laohu8.com/S/PDLI\">PDL BioPharma</a>He held management positions at multinational pharmaceutical companies such as Bayer and CrownBio in Germany, and after completing postdoctoral research at the University of Glasgow in the UK, he conducted scientific research at the University of Louisville School of Medicine in the United States. During his tenure as Senior Vice President of Sino-American Crown Biotechnology, he played a decisive role in formulating and executing the company's strategy and establishing a joint venture with Pfizer.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/462/w550h712/20210727/7570-3cd7c1d54dc532007a1a67b35d002611.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Dr. Xia Yu</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">In the founding team, Xia Yu is responsible for the company's overall strategic planning, business and scientific development direction. Xia Yu said, \"What is needed at the crucial moment for enterprise development is the courage to make decisions and to bear the pressure and responsibility of decision-making. It truly tests the leader's foresight and control over the enterprise's development.\"</p><p><p cms-style=\"font-L\">After achieving fruitful results in the \"original R&D route\" campaign, Xia Yu is now leading Akeso biotech to face the next challenge: product commercialization, moving from biotech to biopharma.</p><p><p cms-style=\"font-L\">According to Xia Yu, \"Some companies may have made it very clear from the very beginning that they are not involved in production or future commercialization, and just do what they are good at, which is also a good business model. But for some companies, such as Akeso Biotech, I don't actually set limits for the future. As long as conditions permit and it aligns with the company's development strategy, we will promote it.\"</p><p><p cms-style=\"font-L\">The first condition, for example, is that I have enough talent and ability to carry out both production and commercialization, which requires a larger corporate development goal to drive it. In addition, as a founder, I also need to have this ideal, which I think is very important. Because the further we reach the production and commercialization stage, the greater the uncontrollability, and courage is essential.</p><p><p cms-style=\"font-L\">Knowing there are tigers in the mountains, they still venture into the tiger's den. This is Xia Yu's perseverance and resilience.</p><p><div><div><img src=\"\"/></div><div>Massive amounts of information and accurate interpretation are available here.<a href=\"https://laohu8.com/S/SINA\">Sina</a>Financial APP</div></div>Editor: Liu Wanli SF014</p><p></div></body></html></p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forbes China Interview with Xia Yu, Chairman of Akeso Biologics: Leaning Towards a Tiger's Den</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForbes China Interview with Xia Yu, Chairman of Akeso Biologics: Leaning Towards a Tiger's Den\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">财经自媒体</strong><span class=\"h-time small\">2021-07-27 17:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><div><p cms-style=\"font-L\">Source: Forbes</p><p><p cms-style=\"font-L\">In the field of pharmaceutical innovation,<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>、<a href=\"https://laohu8.com/S/JNJ\">Johnson and Johnson</a>、<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>、<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>With numerous international giants emerging, it may not be feasible to hone one's skills in ten years.</p><p><p cms-style=\"font-L\">Xia Yu, founder and chairman of Akeso Biopharma, told Forbes China:<span><a href=\"https://laohu8.com/S/600056\">Chinese medicine</a></span><span></span>The true rise of innovation must rely on its own strength, cultivate an innovation atmosphere, build an innovation system, and achieve breakthroughs in innovation achievements. From the perspective of the business model of global industry development, there is no problem with the model of buying, buying, buying, but leading giants in the pharmaceutical industry such as Pfizer, Johnson & Johnson, AstraZeneca, and Novo Nordisk, pharmaceutical companies with a place in the world, should China appear? \"</p><p><p cms-style=\"font-L\">\"China should emerge,\" Xia Yu said firmly, adding that these companies' own R&D and innovation capabilities are key to becoming world-class leaders.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/324/w550h574/20210727/9053-eb59dd1acbf005315f9f014538a392da.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Xia Yu, founder and chairman of Akeso Biotech Co., Ltd.</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">However, where should Chinese pharmaceutical companies that can compete with or even surpass giants place their hopes?</p><p><p cms-style=\"font-L\">In April of this year, Akeso Biotech released its first annual performance report since its listing. The announcement shows that as of the end of 2020, Akeso Biotech's other income and gains exceeded 100 million yuan; R&D investment reached 764.5 million yuan.</p><p><p cms-style=\"font-L\">After ten years of entrepreneurship, Akeso Biologics has finally pioneered a pioneering track in the research and development of original Chinese antibody drugs: among more than 20 drugs under development, 6 are world-first or leading bispecific antibodies, the research and development progress of many cutting-edge target drug candidates is world-leading, more than 20 clinical research projects are in Phase II clinical trials and beyond, and the core world-first bispecific antibodies are about to be launched... A Chinese biotechnology company that has truly gone global through self-development has quietly risen.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/80/w550h330/20210727/0264-3242e677075ee7bd62b8859c7068fc7c.jpg\"/><span></span></div></div><p cms-style=\"font-L\">World's first bispecific antibody cadonilimab</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The buy-buy-buy model can't buy China's Pfizer or China's Johnson & Johnson.</font></p><p><p cms-style=\"font-L\">More than a decade ago, Xia Yu, who had built a comfortable and superior life in a foreign land, returned to China and had the idea of starting a business amidst the bustling crowds of Beijing. As a Chinese person, the first question that comes to Xia Yu's mind is whether China needs original new drugs. Are Chinese people only allowed to use outdated foreign medicines from ten years ago for decades?</p><p><p cms-style=\"font-L\">“Actually, if I were doing the same thing (pharmaceutical research and development) in the United States, I would very likely stop after a certain stage of research and development,” Xia Yu further said. “Because I myself know very well that the investment in production, commercialization, and even clinical trials after research and development is just too huge. But today, with the development of the domestic pharmaceutical industry, whether from the perspective of capital market development or industrial policy support, China actually has the possibility of conquering the global industry high ground.”</p><p><p cms-style=\"font-L\">Of course, a natural shortcoming for Chinese pharmaceutical companies in participating in global competition is their late start and relatively backward overall development level of the industry. \"But the gap does not mean that we cannot achieve world leadership in certain fields, directions, or stages.\"</p><p><p cms-style=\"font-L\">Xia Yu is well aware that there are two paths to choose from when entering the pharmaceutical industry. One path is original research and development, which involves using the company's own internal research and development capabilities to obtain competitive innovative drugs. Another approach is to improve the company's R&D pipeline through external introductions.</p><p><p cms-style=\"font-L\">Ten years ago, the research and development of new drugs in China's pharmaceutical industry was \"poor and white\". Xia Yu still chose the path of originality.</p><p><p cms-style=\"font-L\">Even in recent years, the return of a number of overseas returnee entrepreneurs has actually driven the return of individual advanced technologies. However, Xia Yu has been thinking and practicing how to drive the overall pharmaceutical industry to cultivate and develop in China, and how to establish a truly advanced R&D system in China. Without being in a hurry, or even sacrificing the opportunity to produce advanced products, Xia Yu led Akeso Biotech to invest huge energy in creating an integrated R&D system internally from the very beginning of its establishment.</p><p><p cms-style=\"font-L\">Only under such an innovative R&D system, with this willingness and ideal to grow, from the source of R&D to industrialization, will China's Pfizer and China's Johnson & Johnson emerge in the future.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/40/w550h290/20210727/55da-1b43fa5d55b5db075d491294cb78bfd6.png\"/><span></span></div></div><p cms-style=\"font-L\">Exterior view of Akeso Biotech's Guangzhou base</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">Since its establishment in 2012, Akeso Biologics has focused on developing the world's most cutting-edge tumor immunotherapy antibodies, starting with the most advanced original scientific research and innovation, all the way to the layout of production, commercialization and clinical trials. Currently, Akeso has developed more than 20 innovative drug candidates, of which 13 innovative antibody drugs are in the clinical research stage.</p><p><p cms-style=\"font-L\">\"Actually, not developing original new drugs is an understandable business model. The only problem I think is that this matter has become a red ocean, and anything that enters a red ocean will be terrifying.\" In China, an industrial reality facing drug regulation is that even in 2016, the total R&D investment of pharmaceutical companies nationwide was still less than that of the world's largest pharmaceutical company.</p><p><p cms-style=\"font-L\">\"On the one hand, we need to create fertile ground for industrial development; on the other hand, we must establish a competitive mechanism based on survival of the fittest. The current pharmaceutical giants in the United States are also the result of survival of the fittest after industrial development and market competition. A similar scenario is expected to emerge in China in the future,\" Xia Yu said.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">The stark contrast between ice and fire: the double-edged sword of capital.</font></p><p><p cms-style=\"font-L\">Even in the past two years, with the reform of the Hong Kong Stock Exchange's new share listing system and the introduction of the registration system of the Science and Technology Innovation Board, new financing opportunities and more diverse choices have been provided to pharmaceutical companies with different market orientations, different investor compositions, and different entry and exit mechanisms. What remains unchanged is that the business model for starting a business must be able to withstand the test of capital preservation and appreciation capabilities.</p><p><p cms-style=\"font-L\">Xia Yu recalled that in the early stages of starting a business, if we really couldn't get the financial support of the capital market, we might have survived in other ways, but it is certain that it would have been far from possible to achieve the rapid development we have now. A significant role of capital is to help accelerate the development of enterprises, allowing them to focus more on building robust innovative competitiveness in a competitive environment.</p><p><p cms-style=\"font-L\">　　<a href=\"https://laohu8.com/S/V03.SI\">Startup company</a>The business model chosen at each stage of development will be reflected differently at different stages of development.</p><p><p cms-style=\"font-L\">At the beginning of the business in 2012, drug innovation companies were not as sought after in the capital market as they are now. In order to survive and continue to develop, at the end of 2015, Xia Yu decided to license an innovative product from Akeso Biotech to a giant.<a href=\"https://laohu8.com/S/MRK\">Merck</a>。 \"I think from a business model perspective, at that moment it was definitely a decision that was beneficial to the company's long-term development and supported our long-term development.\" On the other hand, this is the first time that an innovative antibody drug independently developed by a Chinese domestic company has been licensed to a TOP5 international pharmaceutical giant. It has also become one of the landmark events for China's innovative drug industry to truly go international and gain international recognition, and it has also allowed Akeso Biotech to step onto the world stage of drug innovation for the first time.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/117/w550h367/20210727/b886-3bb61d586babf8c3cb5f2b87668503b0.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Production workshop</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">\"Actually, I understand the capital market very well. In the early stages of our business, we spent a lot of time developing the platform, which is why we have achieved many results on the platform now. At Kangfang, while efficiently advancing the clinical development of our existing pipeline, we will focus more on cutting-edge target drugs in product development. This is because we already have a good product foundation and development experience, and have also gained the recognition of investors.\" But if I took investors' money to do 10 years of innovative research and development without any products at all, which investor would agree?</p><p><p cms-style=\"font-L\">If the birth of a new drug is a relay race for various companies in the industry chain, Xia Yu's determination is a marathon.</p><p><p cms-style=\"font-L\">　　<font cms-style=\"font-L strong-Bold\">From studying abroad alone to returning to China to start a business with a market value of 50 billion yuan</font></p><p><p cms-style=\"font-L\">A noteworthy phenomenon is that nearly 20% of the founders of emerging innovative companies in the pharmaceutical industry are women. Having accumulated extensive experience in biopharmaceutical research and development, Xia Yu, as an antibody drug research and development expert, decided to return to China to start a business and found Akeso Biotech with three other returnees. Xia Yu, as chairman, is the only woman in the management team.</p><p><p cms-style=\"font-L\">Xia Yu said, \"Women are more tolerant, more resilient, and more dedicated and persistent in doing something.\"</p><p><p cms-style=\"font-L\">\"But all perfection is relative, and there is no perfect persona in entrepreneurship.\"</p><p><p cms-style=\"font-L\">Just as Xia Yu initially decided to return to China to start a business, even with the support of her daughter's family, she still had to face the incomprehension of those around her. As a mother, shouldn't she be there for her daughter wholeheartedly during this crucial stage of her growth? As a woman, why would she still pursue a so-called career when she is living a comfortable life in middle age?</p><p><p cms-style=\"font-L\">With an incomprehensible sting, Xia Yu and her daughter transformed and grew together. Now, her daughter says that her mother is the person she admires most.</p><p><p cms-style=\"font-L\">At this point, more than ten years had passed since Xia Yu single-handedly founded Akeso Biotech.</p><p><p cms-style=\"font-L\">Following Akeso Biologics' official listing on the Hong Kong Stock Exchange in 2020, its total market capitalization has now reached HK$55 billion.</p><p><p cms-style=\"font-L\">Looking back on her youth, Xia Yu, who was a top student, said, \"I went abroad right after graduating from university. At that time, I relied entirely on myself to get a scholarship and ran abroad with only a few dollars in my pocket. When I went abroad, I found that it was a world of difference from China. I was very nervous at the time and didn't know what would happen next.\"</p><p><p cms-style=\"font-L\">Over the next 20 years, Xia Yu worked at Sino-American Crown Biotechnology,<a href=\"https://laohu8.com/S/PDLI\">PDL BioPharma</a>He held management positions at multinational pharmaceutical companies such as Bayer and CrownBio in Germany, and after completing postdoctoral research at the University of Glasgow in the UK, he conducted scientific research at the University of Louisville School of Medicine in the United States. During his tenure as Senior Vice President of Sino-American Crown Biotechnology, he played a decisive role in formulating and executing the company's strategy and establishing a joint venture with Pfizer.</p><p><div><div><img src=\"http://n.sinaimg.cn/finance/crawl/462/w550h712/20210727/7570-3cd7c1d54dc532007a1a67b35d002611.jpg\"/><span></span></div></div><p cms-style=\"font-L\">Dr. Xia Yu</p><p><p cms-style=\"font-L align-right\">Image source: DR</p><p><p cms-style=\"font-L\">In the founding team, Xia Yu is responsible for the company's overall strategic planning, business and scientific development direction. Xia Yu said, \"What is needed at the crucial moment for enterprise development is the courage to make decisions and to bear the pressure and responsibility of decision-making. It truly tests the leader's foresight and control over the enterprise's development.\"</p><p><p cms-style=\"font-L\">After achieving fruitful results in the \"original R&D route\" campaign, Xia Yu is now leading Akeso biotech to face the next challenge: product commercialization, moving from biotech to biopharma.</p><p><p cms-style=\"font-L\">According to Xia Yu, \"Some companies may have made it very clear from the very beginning that they are not involved in production or future commercialization, and just do what they are good at, which is also a good business model. But for some companies, such as Akeso Biotech, I don't actually set limits for the future. As long as conditions permit and it aligns with the company's development strategy, we will promote it.\"</p><p><p cms-style=\"font-L\">The first condition, for example, is that I have enough talent and ability to carry out both production and commercialization, which requires a larger corporate development goal to drive it. In addition, as a founder, I also need to have this ideal, which I think is very important. Because the further we reach the production and commercialization stage, the greater the uncontrollability, and courage is essential.</p><p><p cms-style=\"font-L\">Knowing there are tigers in the mountains, they still venture into the tiger's den. This is Xia Yu's perseverance and resilience.</p><p><div><div><img src=\"\"/></div><div>Massive amounts of information and accurate interpretation are available here.<a href=\"https://laohu8.com/S/SINA\">Sina</a>Financial APP</div></div>Editor: Liu Wanli SF014</p><p></div></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://finance.sina.com.cn/chanjing/cyxw/2021-07-27/doc-ikqcfnca9352486.shtml\">财经自媒体</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","relate_stocks":{"09926":"康方生物"},"source_url":"https://finance.sina.com.cn/chanjing/cyxw/2021-07-27/doc-ikqcfnca9352486.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2154992231","content_text":"来源：福布斯\n　　医药创新这个赛道，辉瑞、强生、阿斯利康、诺和诺德等国际巨头林立，十年磨一剑也未必可行。\n　　康方生物有限公司创始人、董事长夏瑜向福布斯中国表示：“中国医药创新真正的崛起，必须依靠自身实力，培育创新氛围，打造创新体系，实现创新成果突破。从全球行业发展的商业模式来看，买买买的模式一点问题都没有，但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业，在国际上有一席之地的医药企业，中国要不要出现？”\n　　“中国应该出现。”夏瑜很坚定，而这些企业自身的研发创新能力是企业成为世界级领导者的关键。\n\n\n\n　　康方生物有限公司创始人、董事长夏瑜\n　　图片来源：DR\n　　只是，能与巨头比肩甚至超越巨头的中国医药企业，应该把希望寄托于哪里？\n　　今年4月，康方生物公布了上市后的首份年度成绩单。公告显示，截至2020年底，康方生物其他收入及收益超1亿元；研发投入达到7.645亿元。\n　　创业十年，康方生物终于开拓出一条中国原创抗体药物研发的先行者赛道：20多款在研药物中，6款全球首创或进度领先的双特异性抗体，多款最前沿靶点候选药物研发进度全球领先，超过20个临床研究项目在临床II期及往后阶段，核心全球首创双抗即将上市……一家实打实通过自我研发走出国门的中国生物科技公司悄然崛起。\n\n\n\n　　全球首创双抗cadonilimab\n　　图片来源：DR\n　　买买买模式，买不来中国的辉瑞、中国的强生\n　　十几年前，在异国他乡已打拼出安逸优越生活的夏瑜回国，在北京熙熙攘攘的人群中，冒出创业的念头。作为一名中国人，夏瑜首先想到的问题是，中国是不是需要原创新药？中国人难道只能数十年如一日地用国外十年前的过时药？\n　　“其实，如果我在美国做同样的事情（医药研发），我很有可能做到一个研发某个阶段就不做了。”夏瑜进一步表示：“因为我自己也很清楚，研发后的生产和商业化，甚至临床实验的投入实在太巨大了。但时至今日，随着国内医药行业的发展，无论是从资本市场发展还是产业政策的支持来看，中国其实已经拥有了去攻占全球行业高地的可能。”\n　　当然，参与全球竞争，对于中国医药企业来说，一个天然短板是起步晚、行业整体发展水平相对落后。“但有差距并不代表我们自己在某一些领域、某一些方向、某一些阶段上，就没有办法做到世界领先。”\n　　夏瑜很清楚，踏入医药行业创业有两条路可以选，一条路是原创研发，利用公司自己内部的研发实力获得具有竞争力的创新药；另一条路则是通过外部引进的方式来完善公司的研发管线。\n　　在十年前，当时中国医药行业的新药研究和开发可谓“一穷二白”。夏瑜还是选择了原创的路。\n　　即便近年来，随着一批海归创业者的回归，事实上带动了个体先进技术的回归。但如何带动整体医药行业在中国去深耕建设，如何在中国建立真正先进的研发体系，夏瑜一直在思考与实践。没有急于一时，甚至是牺牲了生产先进产品的时机，夏瑜带领康方生物选择在创立之初，就投入巨大精力，在内部创建一体化的研发体系。\n　　只有在这样的创新研发体系下，具有这种意愿和理想去成长，从研发源头一直做到产业化，未来中国的辉瑞、中国的强生才会出现。\n\n\n\n　　康方生物广州基地外景\n　　图片来源：DR\n　　2012年成立至今，康方生物从最高端的源头科研创新入手，一直到生产、商业化和临床各产业阶段布局，专注开发全球最前沿的肿瘤免疫治疗抗体。目前，康方生物已经开发了超过20个创新候选药物，其中13款创新抗体新药处于临床研究阶段。\n　　“其实不做原创新药也是无可厚非的一种商业模式。唯一我认为出问题的地方是，这个事情变成了红海，而任何事情走入红海就会很可怕。”在中国，药品监管面临的一个产业现实是，即使到了2016年，全国制药企业研发投入总和仍不及全球最大制药企业一家。\n　　“一方面要形成培育产业发展的土壤，另一方面一定要建立优胜劣汰的竞争机制。美国现在的医药巨头，也是经历了产业发展和市场竞争后优胜劣汰的结果。在中国，未来也要出现这样的景象。”夏瑜说。\n　　冰火两重天，资本双刃剑\n　　即便近两年间，随着港交所新股上市制度改革及科创板注册制的推出，给面向市场不同、投资人构成不同、进退出机制考量不同的医药企业，提供了全新的融资机会和更多元的选择。不变的是，创业的商业模式都要能经得起资本保值增值能力的考验。\n　　夏瑜回顾，在创业初期，如果我们当时真的是得不到资本市场的资金支持，可能也会通过其它方式存活下来，但是可以肯定的是，远不可能实现现在的飞速发展。资本其实很大的一个作用是助力，加快企业的发展速度，让企业在竞争的环境中可以更加专心地构建资深的创新竞争力。”\n　　创业公司在每一个发展阶段所选择的商业模式在不同的发展阶段会有不同的体现。\n　　在创业之初2012年，药物创新企业在资本市场并不像现在这样备受追捧。为了生存和继续发展，2015年底，夏瑜决定将康方生物的一个创新产品授权给巨头默沙东。“我觉得从商业模式来讲，在那个时刻一定是一个利于公司长期发展的决定，支撑了我们走向长期发展。”另一方面，这是中国第一款本土企业自主研发的创新抗体药物授权给国际TOP5的制药巨头，也成为中国创新药物产业真正走向国际，并受到国际认可的一个标志性事件之一，也让康方生物在首次登上了药物创新的世界舞台。\n\n\n\n　　生产车间\n　　图片来源：DR\n　　“其实我很理解资本市场。在创业前期我们花了大量的时间做平台的开发，所以才有现在平台上很多的成果收获。时下的康方，我们在高效推进现有管线的临床发展的同时，在产品开发会更聚焦世界前沿的靶点药物。因为我们已经有了很好的产品基础、开发经验，也获得了投资人的认可。但如果我在什么产品都没有的情况下，拿着投资人的钱去做10年的创新研发，试问哪个投资人能答应？”\n　　如果说一种新药的诞生是产业链上各个公司的接力赛，夏瑜决心做的是一场马拉松。\n　　从只身海外求学到归国创业市值500亿\n　　一个值得关注的现象是，在医药行业崭露头角的创新公司中，近20%的创始人是女性。积累了资深的生物药物研究开发经历，作为抗体药物研发专家，夏瑜决定归国创业，与其他3名海归人士创立康方生物。夏瑜作为董事长，是管理团队中唯一一名女性。\n　　夏瑜说：“女性更包容，女性更有韧劲，对一件事情的执着和坚持。”\n　　“但是任何的完美都是相对的，创业没有完美人设。”\n　　就像夏瑜最初决定回国创业，即便得到了女儿家人的支持，仍要面对周遭的不解。已为人母，在女儿成长的关键阶段难道不应该全身心陪伴？作为一名女性，为什么在生活舒适的中年还要再去折腾所谓的事业？\n　　带着不被理解的刺痛，夏瑜和女儿一起蜕变、成长。如今，女儿说，妈妈是自己最崇拜的人。\n　　此时，距离夏瑜一腔孤勇创立康方生物已逾十年。\n　　继2020年康方生物在港交所正式挂牌上市，如今总市值一度冲击550亿港元。\n　　回顾曾经的青春岁月，学霸出身的夏瑜说，“大学一毕业我就出国了。那个时候完全是靠自己拿到一份奖学金，都没揣几块钱就跑出国门，到国外一看跟国内真的是天壤之别。当时很忐忑，不知道接下来会怎么样。”\n　　此后20年间，夏瑜在中美冠科生物、PDL BioPharma、德国拜耳、CrownBio等跨国制药公司担任管理职务，并在英国格拉斯哥大学完成博士后研究工作后，于美国路易斯维尔大学医学院进行科学研究；在担任中美冠科生物技术高级副总裁期间，为公司制定和执行战略以及与辉瑞建立合资企业方面发挥了决定性作用。\n\n\n\n　　夏瑜博士\n　　图片来源：DR\n　　在创始团队中，夏瑜负责公司总体战略规划、业务和科学发展方向。夏瑜说：“在企业发展的抉择时刻，需要的就是拍板的勇气，承担决策的压力和责任。确实考验领导者的深谋远虑和对企业发展的把控。”\n　　在“原创研发路线”战役取得丰硕成果之后，如今夏瑜带领着康方生物要面临的下一个挑战：产品商业化，从biotech走向为biopharma。\n　　在夏瑜看来，“有一些公司可能从创业之初就非常明确说不涉及生产，不涉及未来的商业化，就做自己擅长的事，这也是一种很好的商业模式。但有一些企业，比如康方生物，其实我是没有为未来设限的，只要条件允许，符合公司发展战略，我们就推进。\n　　第一个条件，比如说我是有足够的人才和能力去把生产和商业化都做起来，这就需要一个更大的企业发展目标来推动了。另外，作为创始人，我也要有这个理想，我觉得这非常重要。因为越做到生产和商业化这个阶段，某种意义上说不可控性更强，勇气是必须要有的。”\n　　明知山有虎，偏向虎山行。这就是夏瑜的执着与坚韧。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：刘万里 SF014","news_type":1,"symbols_score_info":{"09926":1}},"isVote":1,"tweetType":1,"viewCount":5375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171666399,"gmtCreate":1626742493411,"gmtModify":1703764212411,"author":{"id":"3583528354923579","authorId":"3583528354923579","name":"锐哥来了","avatar":"https://static.tigerbbs.com/86eb4f1a6da7a549e0c096e4e1890a8e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583528354923579","authorIdStr":"3583528354923579"},"themes":[],"title":"","htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171666399","repostId":"1159080706","repostType":4,"repost":{"id":"1159080706","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626709038,"share":"https://ttm.financial/m/news/1159080706?lang=en_US&edition=fundamental","pubTime":"2021-07-19 23:37","market":"us","language":"zh","title":"[Unusual Movement] Wei Xiaoli recovers from today's losses and rebounds.","url":"https://stock-news.laohu8.com/highlight/detail?id=1159080706","media":"老虎资讯综合","summary":"7月19日，理想汽车、蔚来、小鹏汽车止跌回升，收复今日失地。\n小鹏汽车此前公布旗下搭载量产车规级激光雷达的小鹏P5的预售价格，并宣布开启预售，小鹏P5新车预售价格16-23万元，共推出6个不同续航配置","content":"<p>On July 19,<a href=\"https://laohu8.com/S/LI\">Li Auto</a>、<a href=\"https://laohu8.com/S/NIO\">Nio</a>、<a href=\"https://laohu8.com/S/XPEV\">XPeng Automotive</a>The price has stopped falling and rebounded, recovering the ground lost today.</p><p>XPeng previously announced the pre-sale price of its XPeng P5, which is equipped with mass-produced automotive-grade LiDAR, and announced the start of pre-sales. The new XPeng P5 will have a pre-sale price of 160,000 to 230,000 yuan, with a total of 6 versions with different range configurations to choose from, with a maximum range of 600 kilometers under NEDC conditions.</p><p>Meanwhile, XPeng Motor Company issued an announcement stating that it issued 12.0833 million shares on July 19, 2021, upon partial exercise of its over-allotment option, at an issue price of HK$165 per share.</p><p><img src=\"https://static.tigerbbs.com/f72a193fe4e67d7c18a4cbdff58c6864\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>[Unusual Movement] Wei Xiaoli recovers from today's losses and rebounds.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n[Unusual Movement] Wei Xiaoli recovers from today's losses and rebounds.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-07-19 23:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On July 19,<a href=\"https://laohu8.com/S/LI\">Li Auto</a>、<a href=\"https://laohu8.com/S/NIO\">Nio</a>、<a href=\"https://laohu8.com/S/XPEV\">XPeng Automotive</a>The price has stopped falling and rebounded, recovering the ground lost today.</p><p>XPeng previously announced the pre-sale price of its XPeng P5, which is equipped with mass-produced automotive-grade LiDAR, and announced the start of pre-sales. The new XPeng P5 will have a pre-sale price of 160,000 to 230,000 yuan, with a total of 6 versions with different range configurations to choose from, with a maximum range of 600 kilometers under NEDC conditions.</p><p>Meanwhile, XPeng Motor Company issued an announcement stating that it issued 12.0833 million shares on July 19, 2021, upon partial exercise of its over-allotment option, at an issue price of HK$165 per share.</p><p><img src=\"https://static.tigerbbs.com/f72a193fe4e67d7c18a4cbdff58c6864\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f36b37eb8e9efe8641c7be55a7da26d","relate_stocks":{"LI":"理想汽车","XPEV":"小鹏集团","09868":"小鹏集团-W","NIO":"蔚来"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159080706","content_text":"7月19日，理想汽车、蔚来、小鹏汽车止跌回升，收复今日失地。\n小鹏汽车此前公布旗下搭载量产车规级激光雷达的小鹏P5的预售价格，并宣布开启预售，小鹏P5新车预售价格16-23万元，共推出6个不同续航配置的版本可供选择，NEDC工况下最高续航达到600公里。\n同时，小鹏汽车发布公告，于2021年7月19日因部分行使超额配股权而发行1208.33万股，每股发行价为165港元。","news_type":1,"symbols_score_info":{"09868":0.9,"XPEV":0.9,"LI":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":5165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}